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Abstract
Cardiac arrhythmias represent a health threat worldwide that can end in sudden death. Treat-
ments which include electrical shocks, anti-arrhythmic drugs and ablation show various dis-
advantages such as discomfort for the patients, side and pro-arrhythmic effects as well as
lack of specificity. Moreover, arrhythmias display complex spatio-temporal behaviors mak-
ing their study a challenging task. Cardiac optogenetics is an emerging field used to enable
photo-control of cardiomyocytes by inscribing in them light-sensitive ion channels such as
Channelrhodopsin-2 (ChR-2). Optogenetic stimulation offers a new dimension to investigate
cardiac electrophysiology, from high spatial and temporal resolution to cell specificity and
intensity dependent effects. Previous studies have shown the capability of arrhythmia con-
trol and termination using optogenetics in ChR-2 transgenic mice hearts. However, these
studies relied on local stimulation, which requires either high intensities or long pulses. In
this doctoral thesis I seek to investigate the advantages of globally illuminating the heart as a
method of optogenetic cardioversion. In order to do so, I first characterized the attenuation of
light by the cardiac tissue as well as the response to light stimulation of our model of ChR-2
transgenic mice hearts using the Langendorff-perfusion technique. The effect of the intensity,
pulse width and diameter of the fiber under different experimental conditions involving tyrode,
blebbistatin and the voltage sensitive dye Di-4-ANBDQPQ were investigated in this first step.
Next, I designed an experimental setup that allowed global illumination of the isolated heart.
Arrhythmia induction was facilitated using the drug pinacidil before stimulating the hearts
using pulses of varying intensities and lengths. I also analyzed the efficiency of optogenetic
cardioversion to different arrhythmia wave morphologies, and lastly investigated the time it
takes an arrhythmia to be terminated using light in order to better understand the mechanisms
behind this phenomenon. My results show that both intensity as well as the length of the pulse
affect every aspect of optogenetic stimulation. With a higher effect from intensity, increasing
these parameters leads to a higher success in pacing and cardioversion and shortens the time
required to terminate an arrhythmia. Furthermore, optical mapping analysis allowed the visu-
alization of spatio-temporal electrical waves on the heart surface. It could be shown that most
arrhythmias were terminated by light stimulation of the excitable gap which caused the colli-
sion of the arrhythmic wave. The results obtained improve the understanding of optogenetic
cardioversion from different perspectives and offer a head start in the design of experiments
using large animal models with aims on a future clinical translation.
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1. Introduction
Covering cardiac electrophysiology, image analysis, physics and other fields, “Arrhyth-
mia termination using Global Optogenetic Stimulation in ChR2 mice hearts” is a multidisci-
plinary work performed during my years of PhD training. The keywords in the title of this
dissertation are heart, arrhythmias and optogenetics. Using these three words my PhD project
can be explained as follows.
As we know the heart is the blood pump of the body and it functions via electrical
impulses. An abnormal beating or function in the electrical propagation of the heart is called
an arrhythmia. Electrical stimulation as given by pacemakers or defibrillators can force the
heart to a normal rhythm. I used a new technique called optogenetics that allows stimulation of
the heart using light as a harmless alternative to electrical stimulation. Naturally, hearts are not
sensitive to light, thus transgenic mice hearts were used to perform experiments. These hearts
expressed the light-sensitive ion channel Channelrhodopsin-2 (ChR2) that allows the photo-
control of the membrane potential of cardiomyocytes. Therefore the word “optogenetics”.
Optogenetic cardioversion has been successfully demonstrated by different groups [12,
61, 19]. However, the mechanisms underlying optogenetic cardioversion remain largely elu-
sive. In order to further understand the requirements and factors behind successful optogenetic
arrhythmia termination I hypothesize that utilizing global epicardial illumination would lead
to a decrease in both light intensity and pulse width necessaries to stop an arrhythmic activity
on the heart and at the same time help us understand the events involved in this task.
The dissertation is divided into three parts, which are at the same time composed by
chapters. The first part reviews the topics necessary to understand the work done. Here the
reader can learn about the basics in order to understand the project, including the normal
functioning of the heart, arrhythmias, the principles of optogenetics as well as its application
on the cardiac field. The first part ends with a chapter describing the methods.
Part two constitutes the results; starting from the characterization of the response of the
heart to optogenetic stimulation before moving into the investigation of a more complex task
such as optogenetic cardioversion and lastly performing a deeper look into how optogenetic
cardioversion works. Since each chapter has different research objectives, an introduction,
results, discussion and conclusions section was included to each one. This way the reader
can identify the corresponding meaningful information in a focused and accessible manner.
Chapter 7 wraps the most important outcomes of my doctoral work in a published article
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in Frontiers in Physiology. “Energy-Reduced Arrhythmia Termination Using Global Photo-
stimulation in Optogenetic Murine Hearts” describes the first results obtained with the global
stimulation setup I assembled with the advice of my supervisors. These first experiments
paved the way for more interesting questions and experiments that are investigated in chapters
8 & 9, such as the effects of arrhythmia morphology on cardioversion success and the time
required to terminate arrhythimias using global illumination.
Lastly, part three closes the thesis with a general discussion of the project describing








2.1. The electromechanical pump
The human heart is a muscular organ composed of four chambers, working synchronously
to pump oxygenated blood coming from the lungs into the circulation and non-oxygenated
blood into the lungs coming from the system [24, 32].
Figure 2.1.: Blood flow through the heart. Blood low on oxygen is transported from the sys-
temic circulation and into the right atrium before being pumped from the right
ventricle (RV) into the lungs. Freshly oxygenated blood returns to the heart
through the pulmonary veins and into the left atrium. (Continues on next page.)
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Figure 2.1.: Then the atrium contracts pushing the blood into the left ventricle, which is the
last location before its delivery back into the circulation ejected by the pressure
formed due to the contraction of the ventricular walls. In summary, the right side
of the heart is in charge of forcing the blood to the lungs for its oxygenation, and
after that, the left side forces the blood to the rest of the body for its distribution.
Obtained and modified from [99, 32].
The superior and inferior vena cava transport blood that is low in oxygen, coming from
the upper body and from the trunk and legs, respectively. This blood flows into the right
atrium, and then is pumped by the atrium through the tricuspid and into the right ventricle,
which will be at the same time in charge of pumping it to the lungs. In the lungs, the blood
will go through the process of oxygenation before returning to the heart through the pulmonary
veins. It will reach the left atrium and then the left ventricle (LV). Due to the ventricle’s
contraction, the pressure will rise until it opens the aortic valve and finally gets ejected into
the circulation [24, 32] (Fig.2.1).
The coordinated contraction and relaxation of the four chambers of the heart is ruled by
its electrical activity. Therefore, arrhythmic behavior can lead to a variety of cardiovascular
diseases. In order to understand the underlying mechanisms leading to the heart’s function and
malfunction it is important to know how electricity is generated and distributed in and around
the heart from molecular to organ level [24, 32].
2.2. Electrophysiology of the heart
The heart is composed of millions of cardiomyocytes [48], specialized cardiac cells.
Each cardiomyocyte is a living system on its own, composed of different proteins that syn-
chronized generate changes on the voltage potential of the cell membrane. These changes
lead to the contraction of the cell and at the same time to the ordered contraction of the cham-
bers of the heart and ultimately to the pumping of the blood from the heart and into the body’s
supply system.
2.2.1. The Cardiac Conduction System
The generation and propagation of electrical signals in the heart follows a specific path-
way in order to achieve a synchronous and ordered electrical excitation and further contraction
of the heart. The atrial and ventricular myocytes, compose the major working force and also
posses the ability to conduct electrical impulses.
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The cardiac conduction system is a network comprised of both pacemaker cells, which
are in charge of periodically generating electrical signals [51], and conduction cells, which
are responsible of transporting the signals (bundle of His, left and right bundle branches, and
Purkinje fibers). This way the electrical excitation is generated and spread in a fast and highly
ordered manner.
Figure 2.2 illustrates the cardiac conduction system. The signals originate in the sinoa-
trial (SA) node since it hosts the self-excitatory pacemaker cells. The SA node is located
in the upper part of the right atrium. Therefore, the SA node and its cells are responsible
for the heart beating frequency. A depolarizing current unique to these cells allows them to
rhythmically generate action potentials. The electrical excitation generated by the action po-
tentials is spread to the neighboring cells via specialized connections between cells, the gap
junctions. The electrical wave travels first through right atrium and then through the left, con-
tracting almost simultaneously. From there, the impulse is transported via junctional fibers to
the atrioventricular (AV) node, which is located at the bottom of the right atrium, above the
interventricular septum [34, 65, 81, 80].
Figure 2.2.: The cardiac conduction system. The normal conduction starts at the sinoatrial
node and excites the atria before reaching the atrioventricular node. After reaching
the bundle of His, the pathway is branched into the right and left ventricles. The
differences in the intrinsic pacemaker rates allow normal excitation to occur and
if the SA becomes inactive, then the next structure on the activation pattern would
generate the spontaneous rhythm. Image obtained with permission [81].
The main task of the atrioventricular node is to relay the electrical signal coming from
the SA node to the ventricles. A delay in the signal transmission is also introduced through the
AV junction, while conducting the impulses to the bundle of His. This delay has a functional
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purpose in the pumping action of the heart, allowing the atria to contract completely and empty
the blood into the ventricles before these start to contract.
From the bundle of His the depolarization wave is bifurcated into the right and left bun-
dle branches. The last transmission elements before reaching the ventricles are the Purkinje
fibers, which conduct the impulse at a high speed and spread it to different points of the left
and right ventricular walls. Lastly, the ventricular myocardial depolarization will occur from
endocardium to epicardium and from apex to base, serving the pumping mechanics of the
ventricles [34, 65, 81].
All of these electrical excitation events lead to a contraction, therefore the specific order
and synchronization are crucial in order to pump the blood in an efficient and sustainable
manner. However, synchronicity does not start at the structure level. The generation and
propagation of electrical impulses and at the same time the contraction of the tissue start from
activities at cell level. The next section is dedicated to understanding how an an electrical
impulse generates.
2.2.2. The Cardiac Action Potential
Membrane potential and ion channels
Cardiomyocytes are electrically excitable cells. The selective permeability of their mem-
brane keeps the inner and outer concentration of ions constantly at different levels, creating
a transmembrane potential. The excitation of the membrane by electrical impulses changes
its voltage. These changes lead to the opening of voltage-sensitive ion channels that allow a
quick flow of different ions inside and outside the cell, altering the permeability of the cell
and depolarizing it. Ultimately, the change in membrane potential is followed by the cell con-
traction. Membrane excitability of the cell will depend on different ion channels, pumps and
transporters located through its membrane [32, 81]. In this section we will go through the most
important actors and events that lead to the excitation and contraction of cardiomyocytes.
Ion channels are a group of protein molecules located in the cellular membrane. More
specifically, cross the membrane from the outer part into the inner part in order to create a
route of transport for ions and other specific molecules. Ion channels are distinguished by two
important features: 1) They normally have a selective transportation, allowing only certain
ions to travel across the membrane, and when they are open the ions move by diffusion along
the channel due to the difference in concentrations of the specific ion inside and outside the
cell. This kind of transportation along the membrane is defined as passive. 2) Many of these
channels can open and close. These processes are regulated by either electrical signals (chan-
nels activated by a voltage threshold), or chemical signals (activated by ligands). The three
types of ion channels that play the most important roles in cardiomyocyte electrophysiology
8
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are sodium, potassium and calcium, and they are all regulated by electrical signals [32, 81].
Myocardial cells hold a resting membrane potential of approximately −90 mV. This
potential results from the separation of anions and cations across the membrane and is mainly
determined by the following factors: a) inner and outer concentration of charges (ions), b)
permeability of those ions through the channels, and c) the activity of ion pumps.
Typically, in mammalian myocytes, the concentration of sodium ions (Na+) is higher
outside the cell at approximately 140 mM compared to an intracellular concentration of 5 mM
to 34 mM. In a similar way, calcium (Ca2+) will have an extracellular concentration of ap-
proximately 3 mM, compared to an almost negligible amount inside the cell. Contrary to
these cations, the concentration of potassium (K+) will be 104 mM to 180 mM intracellularly
with just 5.4 mM outside the membrane. These three ions play a critical role in maintaining
the membrane potential at rest and also in inducing the changes in voltage during the action
potential [34].
Action Potential
An action potential (AP) is triggered when the membrane potential is shifted towards a
more positive value of approximately−60 mV due to a depolarizing current normally induced
by neighboring cells through gap junctions. If this stimulus is not large enough to reach the
threshold potential, no depolarization of the cell will occur and therefore, no action potential
will be triggered [81].
If the threshold is reached, a series of opening and closing of different channels will take
place, depolarizing and afterwards repolarizing the cell back to its resting potential. There are
five phases identified during an action potential (Fig.2.3) [33, 81, 34, 59]:
Phase 0 - Rapid Depolarization: The stimulus that depolarizes the cell to the threshold ac-
tivates the voltage-dependent sodium channels (Nav), abruptly changing the permeability of
the membrane to Na+. Due to the difference in concentration, there is a rapid influx of Na+
into the myocyte depolarizing the cell to positive voltages of about 20 mV, almost exclusively
generated by the movement of Na+ cations. The voltage-gated Na+ channels will inactivate
within milliseconds from opening and the permeability of the membrane to Na+ will then
again be decreased. At the end of this phase and with a delay compared to the Na+ chan-
nels, the voltage-sensitive Ca2+ channels will also start to open, increasing the permeability of
Ca2+. At the same time the increased amount of intracellular calcium also induce the opening
of Ca2+ channels inside the cell, at the sarcoplasmic reticulum. This process is called “calcium
induced calcium release” and marks the beginning of the contraction process.
Phase 1- Early Repolarization: Together with the closing of the Na+ channels, there is a small
repolarization caused by the opening of K+ channels, creating an outflow of K+ ions and
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Figure 2.3.: Action potential of cardiomyocytes. The action potential is divided into five
different phases, leading to the various changes in the transmembrane potential
(TMP). Phase 0 is characterized by the rapid depolarization caused by the opening
of voltage-dependent sodium channels. In Phase 1, a small repolarization takes
place due to the efflux of potassium before the plateau phase (Phase 2) where a
balance of inward Ca2+ current and K+ outward currents keeps the voltage stable.
At last, Ca2+ channels close in Phase 3, leading to a repolarization back to negative
values by the continuous K+ currents. During Phase 4 the membrane potential is
stable at the resting state until another stimulus depolarizes the membrane up to
the threshold. Image obtained from [35].
reducing the membrane potential to approximately 0 mV. Inactivation of the Na+ channels
can happen as soon as 1 ms after their opening and excitation of the cell will not be possible
until the majority of the channels recover. Therefore, these channels are the main determinants
of the excitability of the cells of each specific region of the heart.
Phase 2 - The plateau phase: Due to the outflow of potassium and the inflow of calcium
through L-type calcium channels, a plateau phase is reached, where the voltage is stable
around 0 mV for a period of a couple of hundreds of milliseconds. L-type calcium chan-
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nels inactivate at a slower pace compared to other voltage activated channels such as the Nav
and are therefore important contributors to the plateau phase. As mentioned in Phase 1, the
influx of Ca2+ triggers the release of Ca2+ from intracellular compartments, leading to the
contraction of the cell.
Phase 3 - Repolarization: This phase ends the action potential. The gradual inactivation of
Ca2+ channels, together with the K+ outward currents bring the membrane potential back to
its negative values. Moreover, the activity of different ion pumps returns the sodium and
calcium ions outside of the cell and potassium ions to the interior.
Phase 4 - The Resting Phase: This is the original phase of the cell before receiving a new stim-
ulus and triggering an action potential again. In this phase Na+ and Ca2+ channels are closed
and a different K+ current helps maintaining the negative membrane potential. However, Nav
channels will need time to recover before gaining the ability to be excited again. This time is
called refractory period.
Therefore, during the refractory period cells cannot be excited. It is the interval of time
from depolarization to recovery of excitability, and it is related to the action potential duration.
Differences in the refractory period in adjacent regions can aid the generation of arrhythmia
[14]. Arrhythmia and arrhythmogenesis will be explained in Chapter 3.
The expression of ion channels as well as their properties will be different for each
structure of the heart (sinoatrial node, atrioventricular node, atria, ventricles) and will also vary
for different animal species. Therefore, cardiac action potentials have different waveforms
depending on their location. Those differences will contribute to the normal propagation of
excitation waves through the heart. Fig.2.4 A illustrates the waveforms for the excitation
pathway described before.
Fig.2.4 B & C show the differences between human and mouse action potentials. The
latter is shorter and is lacking a plateau phase. These two characteristics can be determined
by a smaller expression of Ca2+ channels on the cell membrane compared to the human heart
and by a larger expression of K+. The differences lead to a faster repolarization of the mem-




Figure 2.4.: Differences in action potentials. (A)Regional differences in the action potential
waveform, and how the regional electrical signals form up the electrocardiogram
(ECG). (B)Human and (C) mice action potential waveform. Images obtained and
modified with permission from [59, 33].
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Cardiac arrhythmias are defined as an abnormal rhythm of the heart, which in other
words would be abnormal electrical activity in the heart. As discussed in Chapter 2, the heart
follows an ordered electrical excitation automatically starting at the sinoatrial node and ending
at the ventricular myocardium. A disruption of the frequency, origin or route of the electrical
propagation can cause or be considered an arrhythmia.
There exists a variety of types of arrhythmias, with also different ways to classify them.
For example by heart rhythm, where a bradycardia is termed for a slow heart rate, tachycardia
for an abnormally fast heart rate, and during fibrillation the pace, amplitude and morphology
are not constant [81, 72]. Arrhythmias can also be classified depending on the region of the
heart where they take place. Supraventricular tachycardia originate in the atria and ventricular
arrhythmia in the ventricles. An additional classification is by the morphology they show in
an electrical recording such as the electrocardiogram, separating them into monomorphic and
polymorphic arrhythmias [82].
When the heart is suffering an arrhythmia, it is unable to properly pump blood from its
chambers and into the circulation. Sudden cardiac death is one the leading causes of natu-
ral deaths in the United States and Europe and approximately half of them are attributed to
ventricular arrhythmia [37].
3.1. Arrhythmogenesis
A healthy heart is able to maintain its function without any anomalies. Arrhythmias
indicate abnormal electrical activity of the heart. The causes of an arrhythmia are broad and
they commonly represent a multiscale problem that can originate from one or many of the
different scales the heart functions: molecular, cellular, tissue, structures, chambers. Alter-
ations in function of the ion channels can promote arrhythmia initiation, and so can changes
in the conductivity of a specific region of the ventricle caused by ischaemia. Nonetheless, the
abnormal electrical activity, leading to the initiation of arrhythmias can present in two forms:
a) abnormal impulse generation which are triggering events, or b) abnormal impulse conduc-
tion, such as heterogeneities or changes in the substrate that affect the pathway of conduction
and can lead to reentry. Both of these mechanisms on their own or combined can provoke the
13
3. Cardiac Arrhythmias
initiation of arrhythmias [66, 39, 23, 33]. In this section we will look into the mechanisms and
focus on ventricular arrhythmias.
3.1.1. Triggering events
One of the most common mechanisms that trigger arrhythmias at cellular level are after-
depolarizations (Fig. 3.1), which are abnormal impulses or extrasystolic membrane depolar-
izations (outside of the normal depolarization) that can lead to action potentials. These action
potentials at the same time can ignite ectopic beats which may result in sustained tachycardia.
Figure 3.1.: Early after-depolarizations and delayed after-depolarizations. EADs take
place during the repolarization (i) of an action potential, while DEAs arise once
the cell is again repolarized (ii). They can both prompt extrasystoles. Image ob-
tained with permission from [39].
Early after-depolarizations (EADs) occur during the repolarization time of a prolonged
action potential (Phases 2-3). This allows the L-type Ca2+ channels to recover. As mentioned
before, these channels are normally open during Phase 2 and are responsible of the plateau in
the action potential. The delayed repolarization is commonly caused by a decreased outward
potassium current, and if it enables enough time Ca2+ channels recover their excitability, re-
open and produce a depolarizing current. This at the same time initiates a positive feedback
on channel opening resulting in the after-depolarization and potentially triggering an action
potential [66, 39, 23, 33].
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Delayed after-depolarizations (DEAs), different from EADs, occur after a full repolar-
ization (Phase 4). They can be elicited from an enhanced Ca2+ release from the sarcoplasmic
reticulum [66, 39, 23, 33].
Other examples of triggering events are alternans and automaticity. During alternans,
cells present changes in the action potential duration, alternating long and short action poten-
tials. Automaticity is when cells that normally do not depolarize on their own do so. Pace-
maker cells of the sinoatrial node are able to periodically undergo spontaneous depolariza-
tion, and this is normal automaticity. Enhanced automaticity (increased rate), or automaticity
acquired by other cells that are not functioning as pacemaker cells can lead to arrhythmia
generation [82].
3.1.2. Heterogeneities or changes in the substrate (Reentry)
Tissue heterogeneities can lead to arrhythmias in different manners, and they are the
basis of most arrhythmias in the clinic. Reentry refers to a circulating electrical wave in which
an impulse travels repetitively around a region of the heart. The prerequisites for the devel-
opment of reentry are: 1) an abnormal electrical circuit around an anatomical block, 2) an
unidirectional block and 3) conduction velocity slow enough to allow recovery of excitability
in time for reexcitation by the circulating impulse. The wavelength is defined as the product
of the effective refractory period by the conduction velocity of excitable media such as car-
diac tissue. If a on of the paths in a circuit bifurcation presents a decrease in wavelength an
excitation loop in this circuit can be created. The path with lower conduction velocity forms
a loop if the propagation is first blocked due to a longer effective refractory period, then a
next wave could travel retrogradely along the path that was originally unexcitable creating the
reentry circuit (Fig.3.2 A). This is called anatomical reentry and many times can give rise to a
monomorphic ventricular tachycardia (MVT) [23, 66, 14].
An arrhythmia can also be triggered without an anatomical obstacle. Slowed conduc-
tion velocity due to a decreased membrane excitability or decreased cell-to-cell coupling may
also result in slowed or blocked conduction. In a different scenario, a heterogeneous area on
the tissue with a longer refractory period can also initiate an arrhythmia. An electrical wave
originating in the periphery would not propagate through this specific area, but instead travel
around it. Afterwards entering it from the opposite direction creating what is called a figure
of eight reentry (Fig.3.2 B). In yet a different scenario, a region of cells with triggering ac-
tivity surrounded by unequal dispersion of refractoriness could start a propagating wave only
towards one direction but not to the other initiating a reentrant activity (Fig.3.2 C) [39, 14].
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Figure 3.2.: Arrhythmogenesis due to heterogeneities in the cardiac tissue. Caption on
next page.
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Figure 3.2.: Arrhythmogenesis due to heterogeneities in the cardiac tissue. (A) An
anatomical reentry can be initiated when an anatomical block separates two path-
ways with different conduction velocities. After a wave originated by the sinus
rhythm propagates across the two pathways (1,2) a second wave coming from an
abnormal activity or source will not be able to travel through pathway 1 (light
gray), since it has an increased refractoriness (3). Once the wave reaches the end
of pathway 2 (white) it will be able to travel retrogradely (4,5) through pathway 1
initiating the re-entrant arrhythmia (5,6). (B) A region with longer refractory pe-
riod can also initiate arrhythmia reentry when an unidirectional conduction block
occurs in this region. An ectopic wave (white arrows) traveling after a sinus wave
(1) would travel around the region presenting the heterogeneity (2,3) and then
retrogradely into it (4) starting the arrhythmic pattern. (C) Reentry can also be
induced when the same region of the cardiac tissue presents abnormal electrical
activity (such as early afterdepolarizations, in this case) and heterogeneities in the
propagation. After a normal excitation, an ectopic activity due to EAD would first
excite the area with highest conductivity and then propagate. Images obtained and
modified with permission from [44, 66]
Even though the mechanisms described before are the most common, there are other
mechanisms based on the same principles that can start arrhythmias. In summary, a combi-
nation or one of the following is needed: a) an ectopic electrical activity or trigger, b) hetero-
geneities in the substrate such as a conduction block or differences in the effective refractory
period or conduction velocity.
3.2. Study of cardiac arrhythmias in isolated hearts
3.2.1. Langendorff perfusion
The Langendorff perfusion is a technique to reanimate isolated hearts in vitro. It has
been used to investigate a number of different physiological phenomena in the heart such as
electrical activity, blood flow regulation, metabolism, effects of drugs, and others. One of the
advantages of the technique are the study of the isolated heart without being influenced by
other organs and systems from the body. This of course at the same time makes the results
obtained harder to directly translate into a clinical scenario [5].
During the experiment the hearts are retrogadely perfused by cannulating the aorta, with
the pressure of the perfusate closing the aorta and allowing it to flow through the coronary
system [81]. This is an advantage especially for the study of cardiac arrhythmias since the
electrical malfunction investigated will not lead to a decrease in perfusion of the heart since it
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will not depend on its own pumping to be perfused.
The heart is suspended in a prewarmed bath to keep it at optimal temperature. The
perfusion flow can be controlled either via constant pressure or constant flow and during the
experiment this and other physiological parameters such as the temperature, pH and electrical
activity can be measured to keep track of the heart’s status. In order to keep the heart close
to a physiological condition, the perfusate is oxygenated with 95% oxygen and 5% CO2 and
heated up to the necessary estimated temperature [5].
Once the perfusion setup is running it can be adapted to the specific needs of the study.
Since in this PhD work I am looking to understand cardiac arrhythmias, the optical mapping
technique was also implemented for some experiments.
3.2.2. Optical Mapping
Optical mapping is a technique based on optical sensors which can be fluorescent dyes or
genetically encoded and are used to track the transmembrane potential or intracellular calcium
concentration of isolated hearts or 2D cardiac cultures. It is a contactless method that has
improved the study and understanding of different electrophysiological phenomena such as
cardiac arrhythmias. This is due to its ability to record action potentials from different regions
of the heart simultaneously that result in the spatiotemporal mapping of travelling waves across
the sample [63, 81].
In order to perform optical mapping of transmembrane voltage (implemented for this
doctoral thesis), the fluorescent voltage sensor is loaded into the sample. Synthetic voltage
sensors can be directly injected to the hearts using the Langendorff perfusion technique. Once
the dye is loaded, a source light with the excitation wavelength is used to illuminate the sample,
resulting in the emission of photons of a characteristic wavelength that can be detected by the
sensor and further analyzed. In order to obtain optimal signals of the phenomena studied,
a proper selection of excitation and emission filters as well as detectors with the spatial and
temporal resolution needed must be chosen [63, 81].
Chapter 7 discusses the setup designed from a Langendorff perfusion system adapted to
obtain optical mapping measurements of cardiac optogenetic experiments for this project and
in Chapter 5 the technical details are also described. In optogenetics, the heart is stimulated by
light. Therefore the setup is capable of stimulating the heart at certain wavelength and exciting
the voltage-sensitive dye at different wavelength. Cardiac optogenetics will be described in
detail in the following chapter.
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3.3. Arrhythmia treatment and the opportunity for
optogenetics
Treatments will depend on the type of arrhythmia the patient is presenting, but there are
generally three types of treatments: electric therapy, antiarrhythmic drugs and ablation [31,
37]. Antiarrhythmic drugs are mainly used in the cases of recurrent symptomatic arrhythmias.
Examples are beta blockers and ion channel blockers. However, in some cases antiarrhythmic
drugs can worsen arrhythmias and by having proarrhythmic effects or result toxic for the
patient [37, 16]. Electrical therapy, in the case of an implantable cardioverter-defibrillator,
aids in the prevention of sudden cardiac death and can decrease the mortality of high-risk
patients. Nonetheless, there is a risk of an inappropriate shocks being delivered [8]. And
shocks (appropriate or inappropriate) are not free of risks. They can cause unbearable pain,
damage to the myocardial tissue, psychological discomfort and increase the mortality of the
patient [7, 52, 47, 37].
Optogenetics is a biological technique that enables light-induced depolarization of cells,
and therefore has a great potential in the treatment of arrhythmias. Even though its use in the
clinics still has different hurdles to face [69], the technique can be used as a tool to investigate
the initiation and termination of arrhythmias at a spatiotemporal resolution uncomparable to
the resolution offered by drugs or electrical therapy and with the promise of non-harming
control of cardiac tissue. The next chapter is focused on describing optogenetics in the cardiac






The word “optogenentic” was introduced by Deisseroth in 2006 as a combination of
optics, genetics and bioengineering in order to control and study neural circuits [22]. Nowa-
days, optogenetics is used to control varied biological mechanisms through the expression of
light-sensitive proteins.
In optogenetics, light sensitivity can be inscribed in cells and tissues, originally in the
form of ion channels and pumps. However, the optogenetics toolbox now includes diverse
proteins that with a shine of light of a specific wavelength can be used to control different
cellular and sub-cellular functions [90, 49, 76]. Potential applications of optogenetics lie in
neuroscience, oncotherapy, cardiovascular diseases, diabetes therapy, gene editing and other
medical fields [95].
There are four main steps in order to apply optogenetics as a method to study living
organisms [64]:
1. Selection or creation of the light activated proteins. The first channels to be tested were
directly taken from algae. However, the advances in bioengineering have led to creation
and modification of different channels and other proteins. Regarding ion channels, the
range of applications has been amplified thanks to the manipulation of their properties.
Some of these are wavelength sensitivity, peak and steady current, delay from stimula-
tion to activation, recovery time after activation and the sensitivity of photocurrent to
changes in light intensity among others [55]. A clear example is ChR2-H134R -a mu-
tant of ChR2 with greater steady current- which is most commonly used in the cardiac
optogenetics field [58].
2. Gene delivery. There are mainly three methods to photo-sensitize cells; transfection,
viral transduction or creating transgenic animals. A promoter can be used when apply-
ing viral therapy, giving optogenetics yet another possibility to make it cell or tissue
specific. However, potential translation into the clinic represents a challenge and the
most promising alternative at the moment appears to be viral gene delivery, which is
still questionable for different safety reasons.
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3. Illumination. One of the key advantages of optogenetics compared to other methods of
stimulation such as electrical or drugs is the spatio-temporal precision offered by light.
Illumination technologies can be at the same time the limiting factor and the facilitator.
The illumination source should depend on the type of control needed to be achieved.
From optical fibers [96], lasers, LEDs ([67]), micro-mirror devices ([19, 77, 50]) to
microscopes [12], and micro-LEDs embedded in a 3D multifunctional integumentary
membrane [94] each one will vary on spatio-temporal resolution, light-crafting capabil-
ities and amount of energy delivered. Optical control of living systems such as the heart
or cardiomyocytes offers a new level of interrogation capabilities that were impossible
to achieve using electrical or drug stimulation.
Figure 4.1.: Optogenetic tools controlling membrane potential. The first applications of
optogenetics were focused on changing the membrane potential of cells. (A) Ion
channels such as Channelrhodopsin-2 (ChR2) and Channelrhodopsin-1 (VChR1)
have been mainly used to depolarize the cells by allowing the entrance of cations,
while ion pumps such as archaerhodopsin-3 (Arch) and NpHR hyperpolarize the
membrane by either pumping cations to the exterior or anions to the interior of the
cell. Moreover, these proteins are sensitive to (B) different wavelengths, therefore
depolarizing and hyperpolarizing proteins could be combined to achieve a finer
control of the membrane potential. Image obtained and modified with permission
from [68].
4. Reading and interpreting the outcome. Some often used examples in the case of cardiac
optogenetics can be the action potential during a patch clamp experiment, electrical
signal such as the ECG using electrodes, or topological information of a monolayer or
an isolated heart using optical mapping. The analysis of one or several outcomes will
help better understand the electrophysiological behaviour of the heart.
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Since this doctoral thesis is focused on the understanding of optogenetic arrhythmia
termination via global illumination, we will mainly focus on steps 3) and 4). For the first
step it is of importance to understand the kinetics of the ion channel used in our model,
Channelrhodopsin-2 (ChR2), and for the second step that we are using a α-MHC-ChR2 trans-
genic mouse model, which expresses ChR2 in >90 % of its cardiomyocytes.
4.1.1. Channelrhodopsin-2 (ChR2)
The identification of Channelrhodopsin-2 in the green algae Chlamydomonas rein-
hardtii and its further cloning and characterization triggered the field of optogenetics as a
technique to control excitable cells via light sensitive ion channels [57]. So far it has been the
most important tool to study both neural and cardiac activity without the need of electrical or
drug stimulation and it is also the optogenetic tool used in this doctoral work.
ChR2 is a non-selective cation channel with its highest affinity to H+, Na+, K+ and
Ca +2 . Once it is illuminated, the opening of the channel will lead to a fast rise of its current
(in approximately 200 µs). ChR2 uses retinal as its photosensing element. Since it is a passive
membrane transport protein dependent on the electrochemical gradients, the current elicited
with its opening will depend on the membrane potential.
Two different characteristic currents can be perceived; the peak current, reached on the
first micro to milliseconds from the moment of illumination, and a steady-current which will
have a lower amplitude and can be sustained for longer. The peak current of channel will
also have a recovery time, therefore if a second light pulse is used to stimulate it, the current
will depend on the time elapsed, and a full recovery can take up to several seconds something
that will not affect the steady current coming afterwards. Closing of the channel will take
approximately 10 ms to 20 ms. [57, 11, 26, 78].
4.1.2. Why optogenetic control?
Genetic targeting presents the possibility of discriminating the rest of the different cells
and tissue that is not subject of optogenetic control or study. Light stimulation enhances even
further the capabilities of spatial and temporal resolution and precision. With these new tools,
a variety of scales can be chosen to control and study.
Moreover, electrical stimulation imposes an injection of current that affects the cell or
tissue without considering the current electrophyiological condition of the target. An effect
provided by an optogenetic stimulus will always be modulated by the ionic balances in and
outside the cell, as well as by the other cells surrounding it, providing a sort-of feedback
response that will manipulate the amplitude of the photo-current injected. Optogenetic control
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Figure 4.2.: Properties of Channelrhodopsin-2. (A)Channelrhodopsin-2 allows cations to
flow with different affinity. The photo-current elicited is both (B) voltage-
dependent and (C) light-dependent. When the membrane potential rests at greater
negative value the current will be larger. Image obtained and modified with per-
mission from [26]
.
generates bio-current, compared to super imposed electrical current that could lead to damage
of the cells.
4.2. Optogenetic control of cardiac electrophysiology
The spatio-temporal control of the electrophysiology of the heart using optogenetics has
been demonstrated with high precision at different scales. From milliseconds to seconds, cell
level to organ level as well as different light intensities and illumination patterns, having an
overview of all the capabilities in optogenetic control is of great importance to understand
the outcome of such stimuli and to find an optimal solution for the control and termination of
arrhythmia in the light-sensitive heart. It is well known that optogenetics offers high spatio-
temporal precision but it is also important to consider that light intensity provides yet another
dimension since different amounts of light will lead to different responses.
In one of the first computational models of cardiac optogenetics Abilez and colleagues
[1] validated with experiments the ability to pace cardiomyocytes via optical stimulation at
different frequencies and the effect of the light intensity on the photocurrent injected into the
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cells. When investigated using patch clamp, Channelrhodopsin-2 (ChR2) current reaches a
peak during the first 20 ms of illumination and later decays to a steady-state current, both
dependent on the intensity of the pulse applied. In a similar manner, lower intensities will
result in longer delays of the action potential generation [11, 1]. Stimulating in a precise time-
controlled fashion, optogenetic stimulation during the generation of an action potential can
shape its morphology depending on the delay from the beginning of the action potential [92].
Optogenetic pacing of ChR2-expressing hearts will also lead to a 1:1 capture of the
cardiac tissue, and for shorter pulses a higher amount of light will be required [11]. Moreover,
the amount of energy needed to pace on the ventricles will be lower than in the atria [11], with
the right ventricle being sensitive to the least amount of light [96]. In vivo spatial precision was
corroborated using optical fibers to stimulate specific regions of the heart that were followed
by varied responses depending on the stimulation place of ChR2 mice hearts [96, 17] (Fig.
4.6 E). In the same study, one more of the advantages of optogenetics was employed, as
specific transgenic expression of ChR2 in either cardiomyocytes or the purkinje fibers was
used to investigate the differences and susceptibilities of arrhythmia triggers between the two
cell types and specific regions of the heart, proving that extrasystoles and ectopies can be
generated by stimulating approximately ten fold less purkinje fibers than cardiomyocytes.
High spatio-temporal control in cardiac monolayers has seen further enhancement. Aided
by technological advances, in this case a digital-micromirror-device (DMD), light was crafted
in order to achieve precise control of excitation waves [15]. Direction of the waves was con-
trolled by a synchronized series of light stimuli, first creating a one-sided conduction block
with a long, high intensity pulse and during the period of refractoriness applying a next short
low intensity pulse to generate a wave that would only travel the opposite direction of the
block. Control of conduction velocity of the traveling waves was acquired by benefiting from
the dimension offered by the manipulation of the light intensity. By applying a sub-threshold
pulse (light at intensities that will not lead to an activation wave), cells’ membranes were
brought close to the excitation point, therefore increasing the conduction velocity once a sec-
ond light pulse triggering propagation was applied. Lastly, by imposing a spiral shaped light
stimulus with opposite chirality, spiral wave chirality manipulation was achieved for the first
time in excitable media.
At the moment of planning and designing optogenetic control, it is also of importance
to consider the delivery method and how each one of these can lead to different spatial distri-
butions of the light-sensitive cells, and at the same time, which kind of illumination is better
suited to the distribution obtained [9].
The knowledge of all these features in optogenetic control of cardiac electrophysiology
paved the way first to understand the mechanisms that can be used to terminate arrhythmias,
and then to optimize arrhythmia control. The different methods and bases of optogenetic
arrhythmia termination are described in the next section.
25
4. Cardiac Optogenetics
Figure 4.3.: Optogenetic control of cardiac electrophysiology. Caption on next page.
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Figure 4.3.: Optogenetic control of cardiac electrophysiology. Experimental and computa-
tional work has shown that the electrophysiological behaviour induced by ChR2
will depend on the intensity of the stimulus. (A) Photocurrents will be larger for
higher intensities, both peak and steady-state currents (B). Additionally, (C) light
stimulation of individual cells, cardiac monolayers or beating hearts will derive
on temporal response and activation of the target, and on single cells (D) higher
intensities will translate into faster triggering of action potentials. (E) Regional
control was also proved using optical fibers to stimulate specific areas of the heart
and confirmed on the ECG recordings. (F)Direction, speed and spiral chirality of
excitation waves on cardiac monolayers was achieved using a micro-mirror de-
vice. Images obtained and modified with permission from [1] for A and C, [11]
for B and D, [96] for E, [15] for F.
4.3. Optogenetic arrhythmia termination
One of the most ambitious and desired goals in the field of cardiac optogenetics is the
possibility of pain-free and therefore harmless arrhythmia termination. A potential appli-
cation could be seen in an optogenetic implantable cardioverter-defibrillator (ICD). Patients
implanted with ICD not only suffer from pain at the moment of the shocks, but also from
depression and anxiety showing a reduction in their self-perceived quality of life, mainly due
to the application of irregular shocks and the development of other symptoms that affect the
patients mentally and physically [79, 89].
The first proof of optogenetics-based arrhythmia termination was shown on monolayers
of neonatal rat atrial cardiomyocytes [6]. Spiral waves were electrically induced and then ter-
minated by photo-stimulation of the Ca2+-permeable channelrhodopsin CatCh [45], which is
also sensitive to blue light. Light pulses of 500 ms at 0.038 mW/mm2 led to arrhythmia ter-
mination in all the cell cultures where CatCh was expressed. Spiral termination was attributed
to the decrease in excitability by the light-induced depolarization that lead to meandering and
collision of phase singularities with one another or with the boundaries (Fig 4.4).
This study demonstrated the potential of light induced arrhythmia control. However, a
translation to clinical applications is still many challenges away. Two of the most immediate
ones are related to the translation from a 2D culture model to a whole-heart model. First,
arrhythmia behaviour is more complex in a heart and the physical boundaries such as the
ones found in a 2D model are not there. And second, light-penetration can become an issue.
Bingen and colleagues relied on homogeneous illumination of the cardiomyocyte monolayers
[6], therefore one can expect that almost all the cells received the same intensity. Achieving
a stimulus as precise and as global as the one achieved by them is a practically impossible
challenge, even without mentioning that simply achieving stimulation of all the cells in the
heart could already be a challenge.
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Figure 4.4.: Effective light-induced spiral wave termination by CatCh expression. (A)
Activation map of CatCh-transduced rat atrial cultures showing spiral arrhythmic
activity before being optogenetically stimulated (left) and after 500 ms of ho-
mogeneous illumination, showing planar wave eletrcial propagation. (B) Rate of
successful reentry termination for CatCh-transduced cultures (n = 31) and cul-
tures transduced only with eYFP (n = 11, control). Image obtained and modified
with permission from [6].
4.3.1. First “optical shocks” in small animal models
Nonetheless, in 2016 three different groups were able to revert arrhythmic hearts ex-vivo
into their normal rhythm via optogenetical control of their electrophysiology. A combination
of two different animal models, using two versions of channelrhodopsins and also diverse
illumination strategies opened the road into a new dimension of cardiac arrhythmia research.
While the works by Bruegmann and Crocini were done on ChR2-transgenic mice hearts [12,
19], Nyns and colleagues stimulated red-activatable channelrhodopsins (ReaChR) in rat hearts
treated with the injection of adeno-associated virus [61].
Since the work of this thesis was performed using ChR2-transgenic mice hearts, the
results obtained in the same model were actually used to set the foundations of the research
performed and will be more broadly discussed. Using the KAT P channel opener pinacidil,
Bruegmann et al. were able to induce arrhythmia in the Langendorff-perfused mouse heart,
and by illumination of the anteroseptal epicardium able to perform optogenetic cardioversion
on the beating heart. KAT P are potassium channels sensitive to adenosine triphophate (ATP)
and have a protective role during ischaemia [28]. Their opening leads to the shortening of the
action potential duration, facilitating the initiation of arrhythmias.
Compared to optogenetic pacing, cardioversion demands increased amounts of energy,
which in optogenetics can be translated into into higher intensities, longer pulses and larger
areas to illuminate. In this experiments it was also demonstrated that for the same reason
length, intensity and area have an influence in the efficiency of the termination attempt (Fig
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Figure 4.5.: Optogenetic defibrillation of the mouse heart by illumination of the epicar-
dial surface. Stimulation of Langendorff-perfused hearts in arrhythmic state us-
ing a 4-pulse protocol shows that efficiency depends on (A) pulse length (n = 7),
(B) area illuminated (n = 9) and (C) the intensity delivered to the cardiac tis-
sue (n = 5). For the parameters tested the pulse length maximum efficiency
appears to be reached between 300 and 1000 ms, while the intensity saturates
at 1.0 mW/mm2. (D) Arrhythmia was induced benefiting from the effects of
pinacidil via electrical burst pacing and the stimulated protocol consisted of 4
light pulses of identical characteristics. Data presented as mean ± S.E.M. Each
data point represents the termination rate in one heart. Image obtained and modi-
fied with permission from [12]
.
4.5). In order to obtain a higher efficiency, the number of pulses was increased to 4, which
allowed them to terminate at a rate of 97 % with stimuli of 0.4 mW/mm2 lasting 1 second on
an area of 143 mm2. Additional experiments of clinical relevance performed by Bruegmann
and colleagues in the same work demonstrated the feasibility of optogenetic cardioversion in
hearts with induced acute myocardial infarction and in a different scenario the termination of
arrhythmia wild type mice heart one year after gene transfer via AAV injection.
The approach of Crocini et al. was different. Even though they also looked to optogenet-
ically terminate arrhythmia they aimed to take full advantage of the spatio-temporal benefits of
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using optogenetics. In order to do this they designed an imaging and stimulation setup using
a macroscope and a laser scanning system based on acousto-optics deflectors. This allowed
them to “draw” different illumination patterns on the surface of the heart (Fig 4.6).
Figure 4.6.: Shaped illumination in optogenetic defibrillation. (A)Success rates for differ-
ent shapes tested. The intensity of the triple barrier is 10 mW/mm2 and whole
LV was illuminated with an intensity of 0.5 mW/mm2. Data presented as mean±
S.E.M. (B)The triple barrier was tested using different intensities as well as two
pulse durations. The highest success rate obtained using 40 mW/mm2 and 10 ms
was also compared to three barriers placed in a different position terminating only
36% of the attempts. Image obtained and modified with permission from [19].
Since the arrhythmias generated in their ChR2-mice hearts consisted of a re-entrant
spiral covering the left ventricle they opted to use a triple barrier stimulation shape (Fig
4.6A) in order to depolarize the ChRh2-cardiomyocytes on this specific areas and generate
conduction blocks along the path of the tachycardia.
With this concept, the triple barrier terminated arrhythmia at a rate of 98% covering
a total area of 0.45 mm2 compared to Bruegmann’s 143 mm2 using a series of 10 pulses of
10 ms at an intensity of 40 mW/mm2, which is 100-fold greater than the intensity used in the
first approach.
As mentioned before, both groups used different manners in order to end arrhythmic
behavior using optogenetics for the first time in the beating heart [20]. An advantage from the
first group was the ability to terminate non-specific arrhythmia and do it at evidently lower
intensities. On the other side it required 4 pulses of 1000 ms with “off” breaks of 1-5 seconds
in between. Altogether this can be a great amount of time considering the physiology and
heart rate of the mouse heart.
The second group, which needed only a total of 100 ms of stimulation and 1000 ms
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to complete the termination protocol suffered a compensation in energy by increasing the
intensity up to 40 mW/mm2, which would need validation of no harm induced on the cardiac
tissue since phototoxicity is one of different challenges to be faced by cardiac optogenetics
[69].
Figure 4.7.: Global illumination of the epicardial surface. A setup composed of three LEDs
surrounding the heart enables simultanous illumination of the whole heart which
could resemble electrical defibrillation. Image obtained and modified with per-
mission from [67].
The most important part of this doctorate work was the aim to use yet a different ap-
proach that would tackle the disadvantages of the two methods previously described, which
are the need of multiple and long stimulation pulses or the need of very high intensities. There-
fore a stimulation setup illuminating the complete surface area of the heart was designed (Fig
4.7). Apart from allowing us to reduce the intensity needed and the length of the pulses, it
would also help us understand how arrhythmia behave in a scenario similar to the application
of electrical shocks, where the complete heart is stimulated. Chapter 7 is dedicated to the
results and findings obtained with this aim.
4.3.2. Mechanisms of optogenetic cardioversion
Sasse and colleagues described optogenetic cardioversion via depolarization using ion
channels as an outcome from two possible mechanisms; conduction block or filling of the
excitable gaps [76]. An excitable gap is the area of the heart or tissue that has been depolarized
and has had enough time to recover from the refractory period, and therefore is again excitable
(Fig 4.8 A).
During conduction block certain volume, thickness or area of the cardiac tissue is il-
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Figure 4.8.: Mechanisms of cardioversion by optogenetic depolarization. (A) After depo-
larization of the cardiac tissue occurs (red), it cannot be excited again for a period
of time while it recovers (yellow), and lastly once it is recovered it is consid-
ered an excitable gap again (green). (B) Arrhythmic spiral wave at different time
points, where the wave front travels and behind it the cardiac media shows refrac-
torines for a period of time before becoming excitable again. (C) A conduction
block consists of continuously illuminating an area of the tissue in order to keep
it in a refractory period until the next arrhythmic wave front rout is blocked by the
illuminated area. (D) Filling the excitable gap consists in illuminating part of the
tissue that can be excitable in order to generate a new wave that would clash with
the arrhythmic wave leading to its annihilation. Image obtained with permission
from [76].
luminated and brought to an unexcitable state long enough to block or disrupt the activation
path of the arrhythmia, therefore halting its activity (Fig 4.8 C). In this case, the amount of
volume stimulated should be enough to properly create the block since a partial block can still
allow circulation of the arrhythmic wave through non-excited or deeper areas of the ventricles
[88, 41]. Filling of the excitable gap consists of stimulating an available region of the tissue
in order to generate a depolarization wave that can collide with the arrhythmia and lead to the
termination of both (Fig 4.8 D).
Creating a conduction block requires continuous stimulation of the arrhythmic wave
path, hence illumination of the deeper layers of the heart will be of importance and can be a
limiting factor. Differently, filling the excitable gap can be accomplished with a lower amount
of light but it requires timing and positioning of the gap.
4.3.3. Determinants in optogenetic cardioversion
As previously mentioned, Nyns and colleagues accomplished optogenetic cardioversion
on rat hearts using the red-activatable channelrhodopsins (ReaChR). More interestingly, they
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demonstrated first that the energy requirements for terminating monomorphic and polymor-
phic arrhythmia are also different. With a stimulation of a 1000 ms-single pulse at an intensity
of 2.97 mW/mm2 on an area of 125 mm2 they achieved a success rate of 97 % in the case
of monomorphic tachycardia compared to only 57 % when a polymorphic tachycardia was
presented [61]. Furthermore, they suggested that stimulating the cardiomyocytes during the
arrhythmia leads to an increase in their action potential duration (APD) which perturbs the
arrhythmia facilitating termination.
In experiments performed on neonatal rat ventricular slices, Watanabe and colleagues
exhibited the importance of penetration depth as a factor to finish arrhythmia using light (Fig
4.9) [88]. Re-entrant arrhythmia were triggered and conduction blocks of different thickness
(transmurality) formed by light-induced depolarization were tested.
Their first step was to test whether termination was possible via global illumination of
the slices. Once this was shown to be successful they moved into illuminating a specific width
while still covering the transmurality or depth on its whole, therefore moving from global to
local illumination. After finding an optimal thickness able to stop the re-entrant activity with
the full depth they decided to further reduce the volume of the stimulus and make it even more
local. They compared the efficiency of termination between 25, 50, 75 and 100% depth, and
the only stimulation volume capable reaching a success rate higher than 50 % was the last one.
This indicates that as long as the arrhythmic wave is left with excitable substrate to travel, the
chances of termination will not increase dramatically.
There have also been different groups doing computational work that have helped in the
understanding of the mechanisms and requirements of optogenetic defibrillation. Karathanos
and colleagues simulated optogenetic termination of ventricular fibrillation (VF) in human
heart models under different parameters [41]. In this model, 58% of the cells expressed a light-
sensitive ion channel and both the endocardial and epicardial surfaces were covered by grids
of optrodes of 1 mm radius with consistent spacing. VF was induced and each termination
attempt consisted in simultaneously turning on all the optrodes.
In order to investigate optimal parameters to achieve this goal, four different versions
of channelrhodopsins were tested; ChR2-H134R (ChR2), which is the same used in the ex-
periments of this doctoral work, a ChR2 version with increased sensitivity (ChR2+), and red
activated variants of these two (ChR2-RED, ChR2-RED+). It is important to note that the
last three are just modeled channels and there is no version of them available for experiments.
Nevertheless, they were simulated in order to investigate the role of light penetration and at-
tenuation of the cardiac tissue. Other parameters varied were the optrode density per area and
the duration of the stimulus.
The results of these simulations exhibited that no arrangement of features where the
blue-sensitive channelrhodopsins were used was successful at any optogenetic defibrillation
attempt, confirming the importance of light penetration. A stimulation pulse of 500 ms using
the highest density of optrodes, in a heart expressing the enhanced-sensitivity version of ChR2
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Figure 4.9.: Effect of illumination volume on the termination of re-entrant arrhythmias
in CatCh ventricular slices. (A) Unsuccessful and (B) successful examples of
cease in arrhythmic behaviour using different transmural illumination. On the
left is shown an activation map before stimulation, followed by the optical signal
obtained before and after stimulation and on the right the path followed by the
electrical activity over time. (C) Effect of transmurality on the termination rate
and (D) the cycle length of the re-entry.(E) All except for one arrhythmia were ter-
minated in the illuminated area, validating termination due to optogenetic induced
conduction block. Image obtained with permission from [88]
.
(ChR2+) activated only 10% of the ventricular tissue. Compared to 46% by solely substituting
the ion channels’ sensitivity from blue to red. Figure 4.10 illustrates the distribution of the
transfection and optrode densities, and the table includes the ratio of ventricular activation
based on different parameters such as the type of ion channel used, the pulse duration and the
optrode density.
The enhancement of all these tested parameters translates into a higher volume of ven-
tricular mass activated and the success rate mechanism is dependent on the stimulation of the
excitable gap. The wavelength affects the penetration depth while the optrode density directly
increases the amount of light. Moreover, a longer pulse will increase the chances of stimulat-
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Figure 4.10.: Proportion of light-activated ventricular tissue. (A) Ventricular model dis-
playing the distribution of the channelrhodopsins (blue) in the non-transfected
tissue (black). (B) Examples of the different optrode densities modeled in hu-
man ventrical optogenetic cardioversion. 1.15/cm2 (left), 2.30/cm2 (middle),
4.61/cm2 (right). (C) Table indicating the proportion of tissue activated depend-
ing on the opsin, density and pulse length used. Image obtained and modified
with permission from [41].
ing cells that with a short pulse would have been illuminated during the refractory period.
To summarize, there are different factors to be considered at the moment of optogeneti-
cally stimulating the heart, and all of these will play a different role in the task of optogenetic
cardioversion.
As mentioned before, the aim of this doctoral thesis was to use global epicardial illumi-
nation of the heart to terminate arrhythmias and investigate the benefits of global illumination
as an alternative to structured or local illumination. Allowing us to apply smaller intensities
and to better understand the behavior of arrhythmia under optogenetic arrhythmia termina-
tion. Moreover, global illumination can offer a closer comparison to electrical cardioversion
where the whole heart is electrically stimulated. The next chapter is focused on describing





5. Materials & Methods
5.1. Light transmittance of the cardiac tissue
The transmittance of light by the heart and different cardiac structures (LV, RV and
septum) was estimated using a setup that consisted of a LED illuminating the epicardial sur-
face and a S120VC photodiode power sensor connected to the PM100D optical power meter
(Thorlabs) to detect the light coming through the tissue across a pinhole of 1 mm in diame-
ter (Figure 6.2). The transmittamce of light was obtained from the ratio of the light coming
through the tissue and the light directly from the LED through the pinhole without any car-
diac tissue. Two LEDS of different wavelengths were implemented. One with a wavelength
of 625 nm (M625L3, Thorlabs) with a bandpass filter (FF02-628/40-25, Semrock) and the
other with a wavelength of 460 nm (M470L3) with a bandpass filter 470(20) nm (ET470/40x,
Chroma). The transmittance of 5 different intensities in the range between 0.5 mW/mm2 to
1.5 mW/mm2 was considered to calculate the mean values of each heart. Light transmittance
was measured in hearts under different conditions; either a) with blood (directly after extrac-
tion of the heart from the mouse), b) after 10 min of Langendorff-perfusion with Tyrode, c)
perfusion with Tyrode for 10 min plus 20 min of perfusion with 5 µM Blebbistatin/Tyrode, or
d) 10 min Tyrode perfusion followed by a bolus injection of 50 µM of the voltage dye Di-4-
ANBDQPQ (Thermo Fisher Scientific) and perfusing for another 5 minutes. Due to the nature
of this experiment, not more than one condition could be tested in the same heart. Transgenic
ChR2 mice hearts with Blood (n = 6), with Tyrode (n = 6), with Dye (n = 3) and with Bleb-
bistatin (n = 4). Wild type mice hearts with Blood (n = 3) and with Tyrode (n = 3).
5.2. Langendorff perfusion
α-MHC-ChR2 transgenic mice were heparinized and anesthetized using isoflurane be-
fore being sacrificed for heart explantation. Light absorption as well as pacing measurements
were performed by Langendorff-perfusing the hearts with a Tyrode solution consisting of
130 mM NaCl, 4 mM KCl, 1 mM MgCl2, 24 mM NaHCO3, 1.8 mM CaCl2 , 1.2 mM KH2PO4,
5.6 mM glucose, 1 % albumin/BSA were aerated with carbogen (95% oxygen and 5% CO2) as
previously described in [70]. For arrhythmia induction, the solution was modified as detailed
later in this chapter. The electrical heart activity was recorded using a monophasic action
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potential (MAP) electrode (BIOPAC Systems, Inc.).
5.3. Investigation of pacing thresholds using optical fibers
The minimum intensity required to pace the heart at each of the ventricles was tested by
positioning the tip of an optical fiber of d= 400 µm connected to a LED of 460 nm in contact
with the center of the right/left ventricle. Two different pulse widths were applied (5 ms and
10 ms), and the intensity was step-wised decreased until the minimum intensity that initiated
a response with a capture of 1:1 of the last 10 pulses from a train of 20 pulses for n = 5
attempts in a row for each heart was found. Threshold intensities were examined for the RV
and LV under normal Tyrode and after the injection of the membrane potential dye. The pacing
threshold of hearts perfused under normal Tyrode vs. the effect of 5 mM Blebbistatin/Tyrode
after 20 min of perfusion was also examined on the LV. N = 6 control hearts and hearts with
blebbistatin, N = 3 hearts with dye.
5.4. Pacing with different intensities, pulse lengths and
surface areas
To investigate the response rate of the heart to different kinds of stimuli, four differ-
ent light intensities were chosen for each optical fiber based on previous results. The inten-
sity units used throughout the thesis are milliwatt per millimeter square (mW/mm2). For the
d= 400 µm (a= 0.126 µm2), the intensities investigated were 1.8 mW/mm2, 2.3 mW/mm2,
3.5 mW/mm2 and 5 mW/mm2 and for the d= 1000 µm (a= 0.785 µm2) the intensities were
lower, 0.4 mW/mm2, 0.7 mW/mm2, 1 mW/mm2 and 2.2 mW/mm2. For each fiber and in-
tensity, the heart was illuminated using a train of 20 light pulses and the last 10 were consid-
ered to determine the capture rate of that heart for that combination. In order, pulses of 1 ms,
2 ms, 3 ms, 4 ms, 4 ms, 5 ms, 6 ms, 7 ms, 8 ms, 9 ms, 10 ms and 15 ms were tested. N = 5
hearts were assayed for d= 400 µm and N = 4 for d= 1000 µm.
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The following methods were first used in “Energy-Reduced Arrhythmia Termination Using
Global Photostimulation in Optogenetic Murine Hearts” [67] (Chapter 7) and they were also
used in Chapters 8, 9 therefore they are described here again as described in [67].
5.5. Arrhythmia Induction [67]
In order to induce sustained arrhythmia we lowered the concentration of KCl to 2 mM,
so that the arrhythmia induction tyrode contains 130 mM NaCl, 4 mM KCl, 1 mM MgCl2,
24 mM NaHCO3, 1.8 mM CaCl2 , 1.2 mM KH2PO4, 5.6 mM glucose, 1 % albumin/BSA were
aerated with carbogen (95 % oxygen and 5 % CO2). Because of a reduction in transmural
dispersion of repolarization the so induced hypokalemia enhances arrhythmia induction [43].
In addition, 100 µM Pinacidil, which is a KAT P channel activator, was applied to shorten the
action potential duration (APD) [30, 91]. The combination of both factors has been success-
fully applied to induce long sustained ventricular arrhythmia in murine Langendorff-perfused
hearts [12]. Sustained arrhythmia was induced by applying 30 electrical pulses with a needle
electrode in the range of 30 Hz to 50 Hz. All perfusion experiments were done at 37 ◦C.
5.6. Global Illumination for Cardioversion [67]
Global illumination was applied in all the optogenetic cardioversion experiments. In
order to achieve a consistent optogenetic stimulation of the whole heart surface and there-
with global illumination, the hearts were vertically arranged surrounded by three blue-light
emitting diodes (blue-LED, Thorlabs) with their wavelengths centered at 460 nm and limited
by a 470(20) nm bandpass filter (ET470/40x, Chroma)(Figure 7.1). Synchronous millisec-
ond control of LED at different intensities was conducted via a function generator (Arbitrary
Function Generator A2230, Agilent Instruments). Intensity measurements were done using
the PM100D optical power meter and the S120VC photodiode power sensor (Thorlabs). Since
the experimental setup consists of three blue-LED spaced at 120◦, the intensity was measured
directly facing each LED from the heart position and the calculated mean was considered the
overall light intensity during global illumination.
To determine the success rate of arrhythmia termination, we induced multiple arrhyth-
mia in each heart and attempted termination 10 times with each light intensity-duration com-
bination. To consider an arrhythmia as sustained we waited for 5 s after induction before
attempting termination, which consisted of illuminating the whole heart by simultaneously
turning on the three LED for the duration and intensity tested. If the arrhythmia stopped
within maximum one second after the conclusion of stimulation, it was considered a success-
ful attempt. In case of failed termination, we applied backup defibrillation, which consisted on
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increasing the intensity and duration of the pulses. To support the defibrillation procedure the
hearts were perfused with maintenance tyrode. The parameter combination with the highest
termination rate and the lowest pulse duration values were determined as the most efficient
ones. They also served as a decision-critical point for parameter change.
5.7. Optical Mapping [67]
To diminish motion artifacts in optical records, the contraction uncoupling reagent Bleb-
bistatin (c = 5µM, Thermo Fisher Scientific) was administrated. Potientiometric staining was
achieved by the red-shifted dye Di-4-ANBDQPQ (c = 50µM, Thermo Fisher Scientific) via
bolus injection. A longpass 685 nm dichroic mirror (FF685-Di02-25x36, Semrock) was inte-
grated to reflect the excitation light from a 625 nm mounted LED (M625L3, Thorlabs) after a
bandpass filter (FF02-628/40-25, Semrock) onto the heart. The emission light was collected
with a 775(70) nm bandpass filter (FF01-775/140-25, Semrock) before reaching the camera
(see Figure 7.1). Epicardial signal recording was done with an electron multiplying charged
coupled device (EMCCD, Cascade 128+, Photometrics) camera with a spatial resolution of
64 pixels x 64 pixels at 1 kHz. Camera control was achieved using custom-made recording
software and the electrical heart activity was recorded using a monophasic action potential
(MAP) electrode (BIOPAC Systems, Inc.).
The obtained fluorescent images were analyzed and processed using MatLab (Math-
Work, Inc.). Briefly, spatial and temporal smoothing filter were applied after pixelwise nor-
malization. Overlapping of the blue light with the emission signal of the dye was removed by
subtracting the average difference in intensities with and without blue light from each pixel
over time. In the cases of short pulses (2 ms, 5 ms, 5 ms and 10 ms), where it was not possible
to obtain an average of the signal during illumination, the illumination frames were completely
removed and replaced by frames with no signal. The estimation of the total surface area of
both ventricles and atria was achieved by reconstructing three-dimensional heart shapes from
photographs using a shape from contour approach as previously described [18]. In total three
hearts were used to calculate an average epicardiac surface area of 274 mm2.
5.8. Statistical tests
Statistical analysis was done applying the Student’s t-test, two-sided and unpaired. A




t-tests are statistical tests used to compare the means of two populations. Also known as
Student’s t-tests, these parametric tests are used to determine if there is a significant difference
between the mean of two samples. The t-test only works for two samples and it helps find a
difference that is unlikely to be due to sampling error or random chance [87, 72].
A paired t-test compares means of two matched or related groups, while an unpaired or
independent t-test compares the means of two unmatched or unrelated groups to determine if
there is a statistically significant difference. Both tests assume that the data was collected from
populations following a Gaussian distribution. In an unpaired t-test it is also assumed that both
populations have the same variance. There are two hypothesis in a t-test: The null hypothesis
states the two means tested are equal, that the difference between them is zero (H0: x = y).
The alternative hypothesis states that there is a statistically significant difference between the
two means tested (H1: x 6= y). This is also known as a two-tailed t-test since either x or y can
be the largest one. Ina one-tailed t test, we have to specify which mean we expect to be the
larger one.
Whenever we perform statistical analysis, we are testing the some hypothesis, this case
the null hypothesis (H0: x = y). The outcome of the statistical test will allow us to accept or
reject the hypothesis and do so with some level of confidence. As mentioned before, in order
to perform this statistical test we are assuming that the distributions of both populations are
normal and that the variances are the same (or close to). Using the sampled data from the















n1 is the number of observations for population x and n2 for population y, and S2x , S
2
y their
respective variances, x the sample average of x and y the sample variance of y.
After the t statistic has been obtained, the t-value is compared to t-values given in a
table for the t-distribution. Our value must be greater than the t-value entry to reject the null
hypothesis with a (1-α) level of confidence for a one-sided t-test or (1-α/2) for a two-sided
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t-test, which is this specific case. α is the level of significance at which we want to accept
or reject our hypothesis. Values of α ≤ 0.05 are commonly used and a standard accepted to
reject the null hypothesis. In other words, a confidence level of 95% or higher. Therefore,
if we want to reject our null hypothesis (H0) with a confidence level of 95%, for a two-sided
t-test our obtained t-value must be greater than t(0.05/2, n1 + n2 -2). If this condition is met,
we can reject H0 and accept H1 with a 95% confidence. n1 + n2 -2 is also known as the degrees
of freedom df.
5.9. Determination of outliers for cardioversion times
Outliers were determined using two different methods. The first method consisted of
identifying the median and discarding from the samples the 10% that had the greatest distance
from it, either larger or smaller. As comparison we also used the ROUT method [56] that
combines robust regression with outlier detection. First it fits a curve using a robust nonlin-
ear regression method that gives very little weight to extreme outliers, then by analyzing the
residuals of the robust fit the outliers are determined by applying a test adapted from the False
Discovery Rate approach. And lastly the outliers are removed and an ordinary least-squares







6. Optogenetic Characterization of the
ChR2 Mouse Heart
Figure 6.1.: Optogenetic pacing of the ChR2 Mouse Heart. (A) The heart is connected to
the perfusion system and an optical fiber is employed to apply 470 nm light pulses
at different widths and intensities while the electrical activity of the heart is being
recorded using a monophasic action potential electrode. The recording can be
seen on the right side; (B) shows 1:1 response of the heart to the last 10 pulses
of the train of 20 light stimuli. (C) represents a different train of light pulses of
lower intensity resulting in pulses that did not reach the pacing threshold to ignite
a response in the Channelrhodopsin-2 heart.
6.1. Introduction and Aim
The energy necessary to stimulate a ChR2-transgenic heart depends on biological and
physical aspects such as the electrophysiological properties of the cell expressing the chan-
nel, expression density and distribution of the opsin, the region of the heart stimulated, the
intensity of the light used as well as the surface area illuminated. The aim of this thesis
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was to apply optogenetics-based cardioversion on the myocardium, therefore both light in-
tensity and duration play a central role. Several other groups have investigated how these
parameters acting on photo-sensitized cardiac tissue. The first experiments performed on sin-
gle cardiomyocytes showed that longer pulses require lower intensities to reach a 1:1 capture
(stimulation:response) rate, that higher intensities induce greater currents and decreases the
time it takes action potential to reach its peak [11]. In the same work, Bruegmann et al.
demonstrated that in vivo atrial stimulation of ChR2-expressing mice hearts demanded more
light than the ventricles and that smaller areas required higher intensities to obtain a similar
response. This could be related to the volume of cardiac tissue stimulated; a smaller area with
a higher intensity would mean that the light is penetrating deeper and could compensate the
total volume of tissue excited. Also in transgenic murine hearts, Zaglia et al. showed the
differences in excitation thresholds between right (lower) and left ventricles for different ar-
eas and intensities [96]. Other results in stimulation thresholds have been shown for different
shapes and areas [19], expression levels [85], as well as in rat models [60].
Light behaves differently under varying conditions, but in a simple scenario light it is
either absorbed or not. What happens and to which proportion will depend in general on two
factors: the wavelength of the photons emitted and the optical properties of the material (in this
case the different types of cardiac tissue). When the light is not absorbed it can be scattered
by the tissue. When the light is absorbed it can lead to many different events such as trigger-
ing chemical reactions (like in the case of Channelrhodopsin-2), it can also be transformed
into heat (which could be harmful for cells), and light could also lose energy and change its
wavelength through fluorescence (being the case of voltage sensitive dye) [86, 36].
In order to estimate and model light attenuation through the cardiac tissue, different
groups have used the Lambert-Beer law [96, 9]:
I(x)= I0e-µx
where I0 is the light intensity at the surface of the cardiac tissue (depth x= 0 mm), µ is the
attenuation coefficient which is defined by the probability of a photon being absorbed in a
specific material per unit path length and it is wavelength dependent, x is the depth of the
intensity estimation and I(x) is the intensity at that depth. The ratio I(x)/ I0 is defined as
transmittance T(x):
T(x)= I(x)/I0 = e-µx
Therefore, the law of Lambert-Beer can be used to estimate the intensities at different depths
into the cardiac tissue as well as the depth reached by blue or red light before a decline in
intensity to levels where an optogenetic stimulus can not be produced.
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Blebbistatin is an electro-mechanical uncoupler used to stop the beating of the heart
while maintaining its electrical activity and it is used in experiments in order to perform optical
mapping. However, studies have shown that the effect of blebbistatin is inhibited via blue light
[74] and that it also exhibits fluorescence upon excitation at 450 nm. Di-4-ANBDQPQ is a
voltage-sensitive dye used in optical mapping. It has its absorption peak at 603 nm, however
it also has a small peak of absorbance around 450 nm [54]. And lastly, blood absorbs and
scatters light at different proportions depending on the wavelength and while its absorption
coefficient for wavelengths ∼450 nm is close to 2 mm-1, its value decreases approximately 10
times in the case of wavelengths ∼650 nm [71].
Optimal optogenetic stimulation and arrhythmia termination will depend on these and
other different factors that will affect how light travels in the cardiac tissue and how much
light is delivered to the light-sensitive channels throughout cardiac walls [9, 41, 12]. Ex vivo
experiments using the Langendorff technique [5] are the main source of research of this doc-
torate work and the conditions in which the heart will be optogenetically stimulated will differ
from experiment to experiment. Moreover, the main subject of my study is the α-MHC-ChR2
transgenic mouse line and these hearts might show different optical properties compared to
wild type mice hearts.
Considering all the above mentioned factors, it was necessary to optogenetically char-
acterize the ChR2 transgenic mouse heart. In other words, to define how this specific heart
model responds to optogenetic stimuli with different paramenters (pulse length, intensity and
area illuminated) and how the addition of substances such as blebbistatin or Di-4-ANBDQPQ
affect the stimulation thresholds compared to a tyrode-only perfusion.
6.2. Results
6.2.1. Light Transmittance by the Murine Cardiac Tissue
Before stimulating the heart under different conditions, I aimed to interrogate light trans-
mittance through the heart under different conditions. The goal of this experiment was to
improve knowledge and understand if a change in the experiment (like adding dye or bleb-
bistatin) can potentially affect stimulation thresholds and how do they affect in general on
any given mouse heart prior to or during the experiment. Therefore, we decided to measure
the mean transmittance of the different mice hearts, ventricles and septum in general without
considering the specific thickness for each one of them, especially considering they were all
healthy mice and no abnormally enlarged or shrunken hearts were expected. This would give
us a head start on where and under which conditions the stimulation thresholds might increase
or decrease.
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In order to estimate the light transmittance by the heart, more specifically by the ventri-
cles and septum, we designed the experimental setup shown in Figure 6.2. The sample tissue
was illuminated and the light intensity transmitted through the tissue was measured using a
photometer through a 1 mm in diameter pinhole. Detailed methods are explained in section
5.2 Materials & Methods.
Figure 6.2.: Setup for light attenuation measurements. Light is emitted from a LED, com-
ing down through the tissue and detected on the other side of a 1 mm in diameter
pinhole. Used with permission from [2].
The differences in attenuation by the cardiac tissue were measured directly after one of
the following conditions:
• perfusion with tyrode,
• perfusion with tyrode and injected with the potentiometric dye Di-4-ANBDQPQ, with
a broad excitation spectra with its peak at 603 nm [54],
• perfusion with tyrode and the electromechanical uncoupler Blebbistatin,
• with blood, right after extraction.
In addition, two different wavelengths were used; 470 nm which is used to stimulate
ChR2, and 625 nm, we used to excite the potentiometric dye during optical mapping and can
also be used in the future to stimulate other opsins. Table 6.1 summarizes the results obtained
shown as percentage of transmitted light (intensity with sample/intensity without sample).
As expected, the RV transmitted more light than the LV, ranging from 5-10 times de-
pending on the condition. When comparing the transmittance of light at different wavelengths,
470 nm transmittance was at least 5 times smaller for all the cases than 625 nm, while in the
LV and RV for the Tyrode perfused case in the ChR2 heart the difference was about 14-fold
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Table 6.1.: Light transmittance by the heart under different conditions. The heart and
its components are enlisted in the main rows on the left side of the table from
most to least light attenuating. On the rows next to them, ChR2-expressing hearts
are separated from the wild type hearts and in the third column they are further
divided into illuminated with either 470 nm or 625 nm. On the columns the various
conditions tested are ordered as tyrode had the highest transmittance of light the
blood the least. The numbers represent the % of light detected by the photometer
coming through the sample from the amount of light detected by the photometer
without sample. ChR2 hearts with blood (n = 6), tyrode (n = 6), dye (n = 3),
blebbistatin (n = 4). Wild type hearts with blood (n = 3), tyrode (n = 3).
and about 6-fold higher. This clearly supports the idea of using red-shifted opsins in order to
increase the amount tissue excited.
Moreover, all the conditions tested affected light attenuation in a different way. The heart
and its elements were most translucent when perfused only with Tyrode, which is important
to keep in mind since ex vivo experiments are an important source of knowledge. When the
dye was added, more light was absorbed and this can change the outcome of an experiment
performed with or without optical mapping. Blebbistatin attenuated even more light than
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the dye, and hearts with blood in their chambers and circulation attenuated light the most.
This behavior was observed for both wavelengths and for the whole heart, LV and septum,
where dye, Blebbistatin and blood significantly increased attenuation compared to the Tyrode
perfused.
Comparing the attenuation by blood, it was at least 2-fold higher than the tyrode solution
for all hearts elements except for the RV. Moreover, illuminating a wild type mouse heart or
ChR2 mouse heart with 625 nm did not make a difference in the transmitted light. On the other
hand, illumination using 470 nm saw a clear drop in transmittance in the case of ChR2 mice
hearts compared to the hearts without the channel, reflecting the absorption by the channels.
Considering measurements of the LV wall thickness (x=1.79 mm) obtained via mag-
netic resonance [73] in experiments from a different group, we can use the Lambert-Beer law
to calculate attenuation coefficients for the ventricle under the different conditions tested as
follows:
µ= ln(1/T(x)) /x
with a wall thickness of x=1.79 mm and T(x) from Table 6.1 Results are shown in Table
6.2. Naturally, the highest attenuation coefficients belong to the conditions with the smallest
transmittance. These results provide an indication on what to expect if the ChR2-mouse heart
were optogenetically stimulated under these circumstances. Therefore the next step was to
measure the response using different illumination parameters.
Table 6.2.: Calculated attenuation coefficient µ of the LV under different conditions. On
the rows, ChR2-expressing hearts are separated from the wild type hearts and in
the third column they are further divided into illuminated with either 470 nm or
625 nm. On the columns the various conditions tested are ordered as tyrode had
the highest transmittance of light the blood the least.
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6.2.2. The Effect of Di-4-ANBDQPQ and Blebbistatin on the pacing
thresholds of the right and left ventricles
After exploring the differences in light attenuation under different conditions we inves-
tigated how these potentially affect the ability to optogenetically pace the heart. Therefore,
we tested the minimum intensities required to pace the heart with at least 10 pulses in a row
when illuminating the RV and the LV with an optical fiber of d=400 µm (Fig. 6.1). We also
compared stimulating hearts with and without bolus injection of the potentiometric dye Di-4-
ANBDQPQ. In order to do this, a train of 20 pulses was used to illuminate the heart and if the
last 10 responded consecutively for a specific intensity, then the intensity would be decreased
until the minimum for that specific heart was found. Using the lowest intensity, the same train
of pulses would be applied for a total of 5 times before establishing it as reproducible. After-
wards, either the dye or blebbistatin would be injected to the heart before performing the same
measurements again, as described in Section 5.3.
As shown in Figure 6.3 A, the intensity required to pace the heart was lower for the RV
than for the LV for both pulse lengths and conditions (with and without Dye) tested. For the
5 ms pulse case, the LV required 4 ± 0.9 mW/mm2, compared to 2.4 ± 0.8 mW/mm2 on the
RV (mean ± s.d.). Furthermore, a significant increase in intensity was necessary to pace the
Dye-injected heart on the LV, jumping to 10.3 ± 4.2 mW/mm2. On the RV the increase was
less pronounced, up to 3.6 ± 1.3 mW/mm2 for the 5 ms case.
Figure 6.3.: Pacing under different conditions. The pacing threshold of the RV was lower
than the threshold of the LV. Even though shorter pulses demanded higher intensi-
ties, the effect of the dye and of blebbistatin was alike for both pulse lengths; while
(A) the dye increased the mean optogenetic pacing threshold, (B) blebbistatin de-
creased it. Plots shown as mean ± s.e.m. N = 6 for control hearts and hearts
with blebbistatin, N = 3 hearts with dye. Performed unpaired t-test (**p<0.01,
*p<0.05 ).
Next, we checked the differences when pacing the LV before and after adding Blebbis-
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tatin to the perfusion solution. After 20-25 min of Tyrode-Blebbistatin perfusion, a decrease in
the pacing threshold intensity was observed. Both 5 ms and 10 ms pulses required about 50 %
less intensity in the blebbistatin case (Figure 6.3 B). Since a tyrode-blebbistatin perfused LV
transmitted a smaller amount of light than a tyrode-only perfused heart (Table 6.1), one could
expect a higher stimulation threshold. I speculate that I observed the opposite, there could be
a rather electrophysiological effect origin than a physical one, deserving special consideration
when planning experiments. This will be further discussed in the Discussion & Conclusions
section.
6.2.3. Pulse length, intensity and surface area determine the optogenetic
pacing threshold
In order to examine the effects of surface area, pulse length and intensity in optogenetic
pacing we used two optical fibers with different diameters ( 400 µm and 1000 µm) to pace the
heart on the left ventricle at four different intensities. For each intensity the capture rate of
the last 10 out of a train of 20 pulses at 9 Hz was measured for pulse widths 1 ms to 15 ms.
The plots in Figure 6.4 display the response of the heart to the different intensity/pulse width
combinations for each fiber.
Figure 6.4.: Pacing with different surface areas. The response rate was step-wise [ms]
tested for (A) d=400 µm and (B) d=1000 µm at four different intensities and they
both displayed the same tendency. Higher intensities reach 1:1 capture at shorter
pulses. Each data point represents the mean ± s.e.m. N = 5 for d=400 µm and
N = 4 for d=1000 µm.
As expected, both cases show similar behavior, with the highest intensities achieving
1:1 capture rate for shorter pulses and the lowest intensities requiring longer pulses in order
to obtain a reproducible response (Figure 6.4). Another behavior in common is the variability
in each data point. This can be explained as follows; it was expected that for each pulse
width/intensity combination each heart would achieve a certain number of captures and we
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would therefore obtain a mean value representing all of the hearts. However, opposite to this,
some hearts responded to 100% of the pulses while other responded to no pulse, leading to the
variability.
Figure 6.5 plots for both surface areas probed the combinations of pulse widths and
intensities that led to a 1:1 capture rate in all the hearts tested. In addition, the energy of
these were also computed and plotted using dashed lines. For both cases, increases in pulse
length allow a decrease in intensity, and vice versa. Similarly, for the same pulse width (7 ms),
illuminating larger areas allows a decrease in intensity. And, when the same intensity was
used (∼2.2 mW/mm2) the fiber with the smaller diameter needed a 9 ms pulse compared to a
2 ms pulse when using the larger fiber.
The amount of energy delivered to the heart during optogenetic pacing remained some-
what constant for each fiber with an average of 2.8 ± 0.5 µJ for the smaller fiber and 3.4 ±
0.4 µJ for the larger one. Since pulse width and intensity compensate each other, an increase
in energy with an increase in surface area illuminated is expected.
Figure 6.5.: Intensities and energies during optogenetic pacing with optical fibers. The
intensity (solid lines) required to achieve 1:1 capture in all the hearts tested is re-
duced for the larger surface area. However, they both show a decrease in intensity
for longer pulses. On the other hand, the energy (dashed lines) doesn’t show a
clear trend. N = 5 for d=400 µm (in red) and N = 4 for d=1000 µm (in green).
6.3. Discussion & Conclusions
In optogenetics there are two key players: opsins which are the actuators, and light
which is the triggering energy activating the actuators. With a deficiency in any of them
optogenetic control could be hindered. Light attenuation is affected by the components of the
heart as well as by laboratory elements used in cardiac research. For these reasons, it is of
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great importance to understand how the conditions of the heart in an experiment affect the
light being delivered to it. In the same line, comparing the attenuation of these conditions
for two different wavelengths and for each area of the heart can help in the design of future
experiments and devices towards the application of cardiac optogenetics in the clinic.
To the best of our knowledge, this is the first optical transmittance investigation compar-
ing the attenuating effects of solutions used in experiments and blood. Zaglia and colleagues
measured penetration of blue light into the ventricular tissue, offering an estimate of light at-
tenuation coefficient of 1/240 µm-1 = 4.16 mm-1, which is close to our attenuation coefficient
obtained from the LV with blood of 3.73 mm-1 [96]. Their results also display that pacing
the left ventricle requires a greater amount of light than for the right ventricle. As expected,
our results show that penetration of red light was clearly greater than for the blue light. Also,
comparing the absorption of both wavelengths in tyrode and blood, the ratio of increased at-
tenuation in blood was always higher in the case of the blue light, which as mentioned in
the introduction, is explained by the higher absorption coefficient of blood to this wavelength
[71].
The results regarding transmittance and attenuation coefficient obtained in this subsec-
tion cannot be straightforward translated to calculate the differences in intensity thresholds
to stimulate the ChR2-mice hearts since there are different factors playing a role such as
concentrations of the dye and blebbistatin, the fluorescence effect of blebbistatin as well as
electrophysiology of the stimulated cells. However, the results can provide an orientation on
to which degree and which solutions attenuate light the most. More specifically for the mouse
model heart used during this project and under the laboratory conditions of the following
experiments.
An interesting point to highlight is how the dyes and blebbistatin can diminish the light
delivered to the photo-sensitive channels. Both increased the coefficient of attenuation of the
heart. However, while the stimulation threshold increased, as anticipated, with the dye, it
decreased with blebbistatin. Blebbistatin has been shown to be inactivated with blue light
[74] and also to show fluorescence and photo-toxic effects in single cells and tissue cultures
[46], explaining the observed increase in absorption in our experiments. Despite a lack of an
agreement on the effects of blebbistatin, some groups have reported alterations on the electro-
physiology of various heart models [10, 83], such as shortening of action potential duration in
rabbit hearts [40]. The evidence shown here might not be enough to prove that blebbistatin is
affecting the sensitivity of optogenetically paced mice hearts, but optogenetics provides a new
tool to design further experiments that could lead to a better understanding of the electrome-
chanical uncoupler. A decrease in the pacing threshold intensity is not expected from a light
attenuating substance. Researchers should take into account all the above mentioned factors
related to the voltage-dye and blebbistatin at the moment of translating the results obtained us-
ing the optical mapping technique, since it is an important source of experiments in all-optical
setups [63].
Lastly, our results regarding the roles of intensity, pulse length and surface area in opto-
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genetic pacing are in accordance with previous experiments [19, 96, 60]. The three parameters
compensate each other, namely, you can increase/decrease one by complementing with one or
the other two in order to obtain the same response. Therefore, short pulses will demand higher
intensities in order to pace the heart and larger areas of stimulation will require lower inten-
sities and/or shorter pulses to obtain a 1:1 capture rate. The advantage of illuminating larger
areas will be especially favorable during the next chapter since optogenetic arrhythmia termi-
nation will be tackled by employing global photostimulation.
The results obtained from this first steps offer knowledge about simple optogenetic stim-
ulation providing the necessary foundations before moving on to more complex scenarios such
as arrhythmia termination. Moreover, the majority if not all of the results obtained with the
mouse model can offer useful perception on what to expect from larger animal models or even
humans.
6.4. Contributions
Part of the experiments were performed by the master students Tsima Abou Kors and
Vishalini Vinkatesan during their master thesis projects. I completely designed and supervised




7. Global Optogenetic Stimulation to
Terminate Arrhythmias
7.1. Introduction and Aim
After characterizing the effects of optogenetic stimulation on the murine heart, it was
possible to use this results in order to translate them to a different task: optogenetic car-
dioversion. This chapter describes the most important part of this PhD work, which lead to
a publication. At the moment of working on this project, all the optogenetic cardioversion
approaches used local stimulation in order to terminate arrhythmias [12, 19, 61].
As described before, when using optogenetic stimulation pulse length, light intensity
and the surface area of illumination play a role in the efficiency of the stimulus. Therefore, we
thought that simultaneously illuminating the whole cardiac surface would lead to a decrease
in one or both pulse length or light intensity used to terminate arrhythmias compared to the
previous methods used. Moreover, up to a certain point it would mimic electrical defibrillation,
where the whole heart is shocked.
Therefore, in order to accomplish the task of illuminating the whole epicardial illumina-
tion, which was the main difference of this method compared to the other groups, I designed
an experimental setup that could synchronously stimulate globally the heart and record optical
mapping data. The setup will be briefly discussed here before attaching the publication gen-
erated. On the part of the analysis, I also focused on how the arrhythmias were terminated,
a feature not investigated before. By computing the time it takes the stimulation to terminate
the arrhythmia I was able to have a better understanding of the mechanisms behind, and this
is also discussed in the paper.
In summary, the aim of this chapter which is mainly composed of a paper, is to describe
global optogenetic illumination as a method to terminate arrhythmias. From its characteriza-
tion, to its advantages, disadvantages and mechanisms. The first step was to build the setup.
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7.2. Experimental setup for global illumination
Figure 7.1.: Global Illumination Setup. (A) Sketch of the setup and all its components. On
the left side the bath surrounded by the three blue-light LEDs and their filters. On
the right side the imaging part composed of the LED to excite the dye as well
as the dichroic mirror and the filter of the emission light coming from the heart.
(B) Photo of the setup placed in the same position as (A). (C) Lateral view of the
bath with the heart vertically arranged. On the left side of the photo the apex of
the heart is in contact with the MAP electrode to record the electrical signal. (D)
Lateral view of the heart in the bath. This time the excitation light of the dye is
irradiating the bath. On the right side of the photo one of the blue LEDs can be
appreciated, with its diameter larger than the height of the heart.
In order to investigate for the first time the effect of global optogenetic stimulation of the
ChR2 mouse heart, this setup had to be built. Since the arrhythmias induced were located in
the ventricles it was a priority to illuminate both ventricles completely with the same intensity.
Hence, using a custom-built hexagonal perfusion bath that would allow vertical positioning
of the heart (Fig.7.1 C) we were able to surround the heart with three illumination sources
(Fig.7.1 C) that would simultaneously illuminate the right and the left ventricles and part of




The stimulation part of the setup was composed of three blue LEDs equally arranged
and distanced around the bath. Before reaching the heart, the light irradiated from the LEDs
was filtered in order to discriminate other wavelengths that could interfere with the optical
mapping. The imaging part of the setup was composed of red-light mounted LED to excite
the voltage dye. This light was also filtered before reaching a longpass dichroic mirror that
would direct the light to the heart and prevent blue light from the stimulation to get in the path
of the camera.
Precisely, the setup was composed of:
• The perfusion bath.
• Three high power LEDs with the wavelength centered at 460 nm (Led Engin, LZ4-
00B208), lenses and bandpass filters 470/40 (Chroma, F49-470).
• Mounted LED 625 nm with a bandpass filter 628/40 (Semrock).
• Longpass dichroic mirror at 685 nm (Semrock).
• Bandpass filter 775/140 nm (Semrock).
• EMCCD camera (Cascade128+, Photometrics)
As described in the manuscript attached in the following section, after the setup was
built the first steps consisted of characterizing the excitation using global illumination, char-
acterize arrhythmia induction, investigate the termination of arrhythmias applying stimuli of
different pulse lengths, analyze the termination time of arrhythmias and the electric phenom-
ena taking place on the surface of the heart during optogenetic arrhythmia termination using
optical mapping. All of this is described on the next chapter composed of the publication.
7.3. Results (publication)
In this section you can find attached the publication ”Energy-Reduced Arrhythmia Ter-
mination Using Global Photostimulation in Optogenetic Murine Hearts” in the journal Fron-
tiers in Physiology. My contribution for this paper was the design, performance and analysis
of all the experiments, as well as writing the paper together with my co-authors.
The Results obtained are the following, and can be found in page 5 of the attached paper:
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7.3.1. Global vs. Local Optogenetic Pacing
Found in Section 3.1 of the attached paper.
7.3.2. Global Optogenetic Cardioversion
Found in Section 3.2 of the attached paper.
7.3.3. Effects of Global Illumination on Arrhythmia Patterns
Found in Section 3.3 of the attached paper.
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Complex spatiotemporal non-linearity as observed during cardiac arrhythmia strongly
correlates with vortex-like excitation wavelengths and tissue characteristics. Therefore,
the control of arrhythmic patterns requires fundamental understanding of dependencies
between onset and perpetuation of arrhythmia and substrate instabilities. Available
treatments, such as drug application or high-energy electrical shocks, are discussed
for potential side effects resulting in prognosis worsening due to the lack of specificity
and spatiotemporal precision. In contrast, cardiac optogenetics relies on light sensitive
ion channels stimulated to trigger excitation of cardiomyocytes solely making use of the
inner cell mechanisms. This enables low-energy, non-damaging optical control of cardiac
excitation with high resolution. Recently, the capability of optogenetic cardioversion was
shown in Channelrhodopsin-2 (ChR2) transgenic mice. But these studies used mainly
structured and local illumination for cardiac stimulation. In addition, since optogenetic and
electrical stimulus work on different principles to control the electrical activity of cardiac
tissue, a better understanding of the phenomena behind optogenetic cardioversion
is still needed. The present study aims to investigate global illumination with regard
to parameter characterization and its potential for cardioversion. Our results show
that by tuning the light intensity without exceeding 1.10mWmm−2, a single pulse in
the range of 10–1,000 ms is sufficient to reliably reset the heart into sinus rhythm.
The combination of our panoramic low-intensity photostimulation with optical mapping
techniques visualized wave collision resulting in annihilation as well as propagation
perturbations as mechanisms leading to optogenetic cardioversion, which seem to
base on other processes than electrical defibrillation. This study contributes to the
understanding of the roles played by epicardial illumination, pulse duration and light
intensity in optogenetic cardioversion, which are the main variables influencing cardiac
optogenetic control, highlighting the advantages and insights of global stimulation.
Therefore, the presented results can be modules in the design of novel illumination
technologies with specific energy requirements on the way toward tissue-protective
defibrillation techniques.
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1. INTRODUCTION
Spatiotemporal dynamics in biological systems, particularly the
control of complex excitation patterns, are a fundamental
nonlinear problem with extensive potential in medical
engineering and therapeutic application. Due to the intrinsic
complexity of cardiac tissue, it is challenging to understand in
detail the underlying biophysical mechanisms of arrhythmia. The
normal sinus rhythm of the heart is triggered by regular, quasi-
planar waves of electric depolarization. Spatiotemporally chaotic
activation patterns have been identified, and are shown to be
responsible for arrhythmic, life-threatening regimes (Davidenko
et al., 1992; Luther et al., 2011; Christoph et al., 2018). The
inferences of patterns in electrocardiograms (ECG), which
showed up as irregular, sometimes aperiodic structures, gave
the impulse to think of arrhythmia and especially of ventricular
fibrillation as an uncontrolled, shivering activation of heart
muscle. Thereby the underlying patterns are results of multiple
erratic excitation waves changing in direction and shape. The
complexity of wave patterns, leading to spatiotemporal chaotic
regimes, is a consequence of the non-linearity. The dynamical
processes are characterized by the annihilation of interacting
waves, a mechanism also found in other physical systems
(Panfilov and Holden, 1990; Jalifé et al., 1998). State-of-the-art
therapies include high energy electrical shocks applied either
external or internal to defibrillate the heart. These, for the patient
mostly painful, shocks terminate the chaotic spreading activity
almost certainly, but are suspected to worsen the existing tissue
conditions mostly due to their potential electroporating effect
on cardiomyocytes. Hence, they also serve as trigger for new
arrhythmia with increasing probability over time. Much work
has been devoted to the search for improved therapies (see
e.g., Zipes and Jalife, 2009). Methods such as Anti-Tachycardia
Pacing (ATP), already used in implantable devices, involve
very small electrical currents delivered by a single electrode.
Provided that the pacing frequency is high enough, ATP can
terminate arrhythmia with a fairly high success rate (Wathen
et al., 2004). Regardless, even with a high success rate the
case of failure can never be disesteemed. Especially stationery
vortex-activities are difficult to terminate with only one pacing
electrode, which is not close enough to the pinning region. So it
is not astonishing that several research groups are investigating
advanced implementations of ATP compared to the traditional
applied defibrillation shocks (Efimov et al., 2000; Exner, 2005).
In addition to the ATP, the Low-Energy Anti-Fibrillation Pacing
(LEAP) method was announced. It consists in pacing the
tissue with an externally applied electric field. In vitro and in
vivo experiments have provided ample evidence that LEAP
significantly reduces the energy necessary to terminate atrial and
ventricular fibrillation (Fenton et al., 2009; Luther et al., 2011)
by using repeated stimulation with fields of lower amplitude.
One crucial feature of LEAP is that it is based on multiple
virtual electrodes induced by intrinsic obstacles. Referring to
former in vitro and in vivo experiments (Exner, 2005), especially
defibrillation approaches implementing multiple pacing sites
have significant influence on arrhythmia specific excitation
patterns resulting in rapid synchronization. Anyhow, in order
to stimulate at multiple pacing sites either multiple implanted
electrodes or specific electrical fields are necessary, which raises
obvious translational hurdles. Also, all these valuable methods
are still based on electrical shock application, which in turn
can never be fully acquitted of potential worsening side effects.
Consequentially, the evaluation of new cardiac treatments with
side effect diminishing properties but fairly high success rates has
to be brought into focus. At this point patterned light control of
optogenetically modified cardiac tissue gives the opportunity to
specifically stimulate well-defined tissue regions without critical
Faraday reactions. Optogenetic photostimulation uses light of
specific wavelengths to activate light-sensitive ion channels,
which works without former electrically induced membrane
potential changes (Bruegmann et al., 2011; Deisseroth, 2011).
Recently, optogenetic cardioversion methods applying localized
photostimulation were shown to be feasible (Zaglia et al., 2015;
Bruegmann et al., 2016; Crocini et al., 2016; Nyns et al., 2016;
Richter et al., 2016). Although much effort was put into the
characterization of locally applied light intensity and energy
(Bruegmann et al., 2010; Zaglia et al., 2015; Diaz-Maue et al.,
2018) the underlying dependencies of light intensity, pulse
duration and successful cardioversion remains somehow elusive.
However, recent studies showed that inducing multi-centered
excitation within the arrhythmic tissue leads to a better control
of spatiotemporal wave patterns, typical for fibrillation (Pumir
et al., 2007; Luther et al., 2011; Janardhan et al., 2012). Having
this in mind, successful global photostimulation would represent
the maximum number of available pacing sites. In comparison
with the conventional high-energetic electrotherapy, global
photostimulation could overcome adverse side-effects like
electroporation or unwanted co-stimulation of sensible neurons
responsible for pain sensation during defibrillation. Indeed
there still remain some questions to be solved before global
illumination or multi-site photostimulation could count for
reliable defibrillation.With regard to potential clinical translation
especially the dependencies between the minimal required light
intensity and pulse duration as well as the applied over-all energy
are important for the design and optimization of implanteable
light-emitting devices. Furthermore, the investigation of
global photodefibrilation and the underlying spatiotemporal
mechanisms could help to deepen our understanding of the
mode of action of conventional electrotherapy.
In the present study, we determine the threshold value of the
applied global photostimulation as a function of the intensity and
pulse duration, and we compare our experimental results with
other photostimulation data. Anothermain question is whether it
is possible to terminate arrhythmia like patterns by light-induced
excitation.
2. MATERIALS AND METHODS
All experiments were done in accordance with the current
version of the German animal welfare law and were reported
to our animal welfare representatives; the application for
approval of animal experiments has been approved by the
responsible animal welfare authority (Lower Saxony State Office
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for Consumer protection and Food Safety). Humane welfare-
oriented procedures were carried out in accordance with the
Guide for the Care and Use of Laboratory Animals and done
after recommendations of the Federation of Laboratory Animal
Science Associations (FELASA).
2.1. Langendorff Perfusion
The presented experiments are based on retrograde Langendorff
perfusion using a constitutive transgenic mouse model, α-
MHC-ChR2, which restricts expression of channelrhodopsin-
2 (ChR2) to cardiac tissue. The ChR2 expression was proven
by biomolecular protocols. The perfusion protocol includes
two different tyrode solutions, either for arrhythmia induction
or maintenance. The maintenance tyrode composition was
described elsewhere (Richter et al., 2016). Briefly, 130mM
NaCl, 4mM KCl, 1mM MgCl2, 24mM NaHCO3, 1.8mM
CaCl2, 1.2mMKH2PO4, 5.6mM glucose, 1% albumin/BSA were
aerated with carbogen (95% oxygen and 5% CO2).
2.1.1. Arrhythmia Induction
In order to induce sustained arrhythmia we lowered the
concentration of KCl to 2mM, so that the arrhythmia induction
tyrode contains 130mM NaCl, 2mM KCl, 1mM MgCl2, 24mM
NaHCO3, 1.8mM CaCl2, 1.2mM KH2PO4, 5.6mM glucose, 1%
albumin/BSA were aerated with carbogen (95% oxygen and
5% CO2). Because of a reduction in transmural dispersion of
repolarization the so induced hypokalemia enhances arrhythmia
induction (Killeen et al., 2007). In addition, 100 µM Pinacidil,
which is a KATPchannel activator, was applied to shorten the
action potential duration (Wilde, 1994; Glukhov et al., 2010).
The combination of both factors has been successfully applied
to induce long sustained ventricular arrhythmia in murine
Langendorff-perfused hearts (Bruegmann et al., 2016). Sustained
arrhythmia was induced by applying 30 electrical pulses with
a needle electrode in the range of 30–50 Hz. To diminish
motion artifacts in optical records, the contraction uncoupling
reagent Blebbistatin (c = 5 µM, Thermo Fisher Scientific) was
administrated. Potientiometric staining was achieved by the
red-shifted dye Di-4-ANBDQPQ (c = 50 µM, Thermo Fisher
Scientific) via bolus injection. All perfusion experiments were
done at 37 ◦C.
2.1.2. Optical Mapping
A longpass 685 nm dichroic mirror (FF685-Di02-25x36,
Semrock) was integrated to reflect the excitation light from a
625 nm mounted LED (M625L3, Thorlabs) after a bandpass
filter (FF02-628/40-25, Semrock) onto the heart. The emission
light was collected with a 775± 70 nm bandpass filter (FF01-
775/140-25, Semrock) before reaching the camera (see Figure 1).
Epicardial signal recording of the anterior wall was done with an
electron multiplying charged coupled device (EMCCD, Cascade
128+, Photometrics) camera with a spatial resolution of 64 × 64
pixels (133 µm per pixel) at 1 kHz. Camera control was achieved
using custom-made recording software and the electrical heart
activity was recorded using a monophasic action potential
(MAP) electrode (BIOPAC Systems, Inc.).
2.2. Optogenetic Illumination Strategies
We employed local and global illumination to stimulate
the heart, whereby only global illumination was used for
cardioversion. Local illumination was achieved by positioning
the tip of an optical fiber of  = 400 µm in contact with
the left ventricle. On the other hand, in order to achieve a
consistent optogenetic stimulation of the whole heart surface and
therewith global illumination, the hearts were vertically arranged
surrounded by three blue-light emitting diodes (blue-LED,
Thorlabs) with their wavelengths centered at 460 nm and limited
by a 470± 20 nm bandpass filter (ET470/40x, Chroma) (see
Figure 1). Synchronous millisecond control of LED at different
intensities was conducted via a function generator (Arbitrary
Function Generator A2230, Agilent Instruments). Intensity
measurements were done using the PM100D optical powermeter
and the S120VC photodiode power sensor (Thorlabs). Since the
experimental setup consists of three blue-LED spaced at 120◦, the
intensity was measured directly facing each LED from the heart
position and the calculated mean was considered the overall light
intensity during global illumination.
To minimize effects of potential edema as well as metabolic
changes during repeated arrhythmia periods on the defibrillation
success rate, we limited the experimental time to 2 h and a
maximum number of defibrillation attempts of 50.
2.3. Data Analysis
The obtained fluorescent images were analyzed and processed
using MatLab (MathWork, Inc.). Briefly, spatial and temporal
smoothing filter were applied after pixelwise normalization.
Overlapping of the blue light with the emission signal of
the dye was removed by subtracting the average difference in
intensities with and without blue light from each pixel over
time (see Figure S1). The estimation of the total surface area
of both ventricles and atria was achieved by reconstructing
three-dimensional heart shapes from photographs using a shape
from contour approach as previously described (Christoph et al.,
2017). In total three hearts were used to calculate an average
epicardiac surface area of 274mm2. Statistical analysis was
done by Student’s t-test (one-tailored and unequal variance)
comparing each increasing step with the following value.
Throughout the text results are indicated with ± standard
deviation, unless otherwise noted.
Concerning local and global pacing experiments a train of
20 pulses was applied, whereby only the last 10 pulses were
considered for the analysis. The minimum pulse lengths needed
to reach 1:1 capture in all the tested hearts for different intensities
were investigated. Each light intensity was tested in combination
with maximal four different pulse duration values.
To determine the success rate of arrhythmia termination,
we induced multiple arrhythmia in each heart and attempted
termination 10 times with each light intensity-duration
combination. To consider an arrhythmia as sustained we waited
for 5 s after induction before attempting termination, which
consisted of illuminating the whole heart by simultaneously
turning on the three LED for the duration and intensity tested. If
the arrhythmia stopped within maximum 1 s after the conclusion
of stimulation, it was considered a successful attempt. In case
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FIGURE 1 | Global illumination and optical mapping setup. (A) The heart is perfused in a bath surrounded by three blue-LED for panoramic photostimulation. Light of
a 625 nm LED is reflected via a dichroic mirror onto the heart surface. Emission was recorded through a 775± 70 nm bandpass filter and an EMCCD camera at 1 kHz.
Global illumination is reached via overlapping light cylinders. (B) Activation maps in posterior view of the heart of spontaneous sinus rhythm and stimulation examples
electrically (electrode position is marked with an asterisk) as well as by global illumination. (C) Exemplary activation maps in anterior view of the heart of induced
cardiac arrhythmia and collision of waves leading to annihilation of arrhythmic pattern. Color-bars indicate activation time in ms and the scale-bars mark 2mm. A
movie of the wave collision is available as (Supplementary Material Movie 1). LV - Left Ventricle, RV - Right Ventricle.
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of failed termination, we applied backup defibrillation, which
consisted on increasing the intensity and duration of the pulses.
To support the defibrillation procedure the hearts were perfused
with maintenance tyrode (as described in section 2.1 and 2.1.1).
The parameter combination with the highest termination rate
and the lowest pulse duration values were determined as the
most efficient ones. They also served as a decision-critical point
for parameter change.
3. RESULTS
3.1. Global vs. Local Optogenetic Pacing
To characterize successful cardiac photostimulation, we tested
the necessary pacing parameters to achieve 1:1 capture with
respect to different pulse durations and light intensities. In order
to avoid potential photochemical reactions and other side-effects
stimulation light was turned off after every pacing.
First, global pacing was applied. Table 1 gives an overview of
the step-wise measured intensities in relation to pulse duration
and success rate. Our results prove that a shorter pulse duration
correlates with higher intensities needed to gain 1:1 capture.
The shortest pulse duration to successfully pace was tgpacing =
3ms applying an intensity of Igpacing = 113 µWmm
−2 (N =
6). For pacing with 20ms pulses successful pacing required an
intensity of Igpacing = 19.6 µWmm
−2. Thus, constituting the
lowest intensity reported to pace an optogenetic murine heart
by photostimulation so far. Pacing the heart with Igpacing =
140 µWmm−2 was also tested for tgpacing = 2ms, but could
only be considered successful in one heart. Figure 2 shows
the intensities and energies necessary to pace the heart with
1:1 capture at different pulse lengths using global stimulation.
The graph shows that the energy necessary to pace at different
intensity and duration combinations remained constant at an
average of Egpacing = 98± 5 µJ.
For comparison, we also conducted local photostimulation.
Considering an increase in intensity required to pace the heart
when stimulating smaller areas, we measured the intensity
necessary to achieve 1:1 capture using an optical fiber of
Afiber = 0.126mm
2 with a tlpacing of 3ms, 7ms, 9ms and 15ms.
Compared to global pacing, all the intensity values required to
obtain 1:1 capture were increased by minimum one order of
magnitude with a maximum of Ilpacing = 1.77mWmm
−2.
In the course of these experiments, it could be observed that
the average energy delivered to the epicardium is constant for
both global and local illumination. In spite of the clear increase
in intensity, it is in average 30-fold lower when pacing locally
than globally, at Elpacing = 2.8± 0.6 µJ and Egpacing = 98± 5 µJ,
respectively.
3.2. Global Optogenetic Cardioversion
In order to find the optimal parameters for optical cardioversion,
we induced cardiac tachyarrhythmia applying Pinacidil and
rapid electrical pacing. Therewith 75% of all arrhythmia lasted
more than tarr = 5 s (59 out of 79 induced arrhythmia). We
considered the tarr = 5 s duration as threshold for classification as
sustained, since about 90% lasted for tarr ≥10 s. Non-sustained
arrhythmia shorter than the threshold lasted on average tarr =
1.5± 1.0 s (Figure 3). The average arrhythmia frequency was farr
= 24± 5Hz, and one third of all induced arrhythmia lasted tarr
≥ 60 s. Optical Mapping data showed multiple vortex-like wave
dynamics, hence proving the successful induction of ventricular
arrhythmia (Figure 1C).
3.2.1. Optical Parameter Characterization
Our measurements concerning global optogenetic photo-
defibrillation were triggered by Bruegmann et al. (2016), where
local illumination cardioversion was first achieved by using an
intensity of Icv(Brueg.) = 0.40mWmm
−2 comprising a surface area
of Aheart(Brueg.) = 143mm
2 with a 1 s pulse. In order to match
the postulated amount of energy delivered by Bruegmann et al.
[Ecv(Brueg.) = 57.2mJ] with our global illumination, which spans
a larger epicardial surface (Aheart = 274mm
2), we modulated
the pulse duration by keeping the intensity constant at Icv =
0.42mWmm−2. Figure 4 shows the main results of the photo-
defibrillation attempts. One single long stimulation pulse led to
a successful arrhythmia termination in 82% of the experiments,
which is comparable to the results obtained by Bruegmann et al.
Subsequently, we assessed the influence of light intensity
by maintaining the pulse duration constant at tcv = 500ms.
While all tested light intensities successfully terminated the
arrhythmia, a decrease in light intensity correlated with a
significant depression in cardioversion efficiency (Figure 4B).
At the most efficient light intensity of Icv = 0.79mWmm
−2, a
success rate of 96± 2% [mean ± standard error of the mean
(SEM)] was achieved. However, a decrease in intensity by 40-fold
still managed to revert the heart rhythm in more than 30% of the
attempts for the hearts tested (N = 6).
Afterwards, to evaluate the effect of pulse duration we kept
the light intensity constant at Icv = 0.79mWmm
−2 and applied
pulses shorter than tcv = 500ms. However, no significant change
in termination rate was found for pulse durations of 500, 250,
100, and 10 ms. A shortening of pulse duration from 500 to
10 ms resulted in a decline of 13% of arrhythmia terminated
(Figure 4B). Supposing the parameter combination of tcv =
10ms and Icv = 0.79mWmm
−2 is as efficient as tcv =
500ms at the same light intensity, in the following we tested a
constant pulse duration of tcv = 10ms while step-wise increasing
light intensity from Icv = 0.08 to 1.1mWmm
−2. Thereby we
obtained successful termination in 92± 4% of the experiments.
Pursuing a wider comprehension of the effects of intensity and
duration on global light-induced arrhythmia termination, we
then experimented with 1 s long pulses, where an efficiency of
96± 2% was achieved with Icv = 0.56mWmm
−2.
3.3. Effects of Global Illumination on
Arrhythmia Patterns
Since the 1 s stimuli lasts multiple tachycardia and sinus rhythm
cycles, we identified that the transition from an arrhythmic
state to the natural sinus frequency took place at different
time points from the onset of stimulation. The electrical signal
shown in Figures 4A,C shows a clear sinus activity even
before the photostimulation has ended. To estimate the time
between the beginning of stimulation and the moment of optical
cardioversion, we defined two characteristic points in time of
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TABLE 1 | Measured pulse duration and light intensity combinations.
Light intensity [µWmm−2]














20 100 ± 0
15 23 ± 11 100 ± 0
12.5 40 ± 8.9 100 ± 0
10 100 ± 0
9 61 ± 8.8 100 ± 0
8 14 ± 7.1 93 ± 5.2 100 ± 0
7 20 ± 7.9 100 ± 0
6 6.5 ± 3.6 90 ± 4.7 100 ± 0
5 13 ± 7.2 100 ± 0
4 86 ± 6.9 100 ± 0
3 100 ± 0
2 5.2 ± 2.3 57 ± 10
Inscribed is the averaged success rate [%] ± SEM of 1:1 capture during global illumination. The visible trend within the success rate regarding the dependency of light intensity and
pulse duration is also mirrored in a constant energy level. Highlighted values indicate the most efficient pulse duration and light intensity combinations, which are drawn in Figure 2B
together with the corresponding energy values. The shown values are based on 23 measurements from N = 6 hearts.
the MAP signal (Figure 4C). First we define tlast as the moment
when the last peak of the arrhythmia occurred, and second tsin
as the time point when the sinus rhythm signal first appeared.
These two values were calculated for all the successful arrhythmia
terminations of different intensities for the 1 s pulses. Figure 4D
illustrates the percentages of tlast and tsin for four time lapses. it
can be observed that tlast occurred at≤ 60ms of stimulus for 81%
of the cardioversions when triggered with Icv = 0.56mWmm
−2.
However, this seems to depend on the light intensity, since
cardioversions triggered with Icv = 0.25mWmm
−2 showed this
phenomenon in 55% of the cases and with an intensity of
Icv = 0.08mWmm
−2 in only 30%. Furthermore, tsin ≤215ms
occurred in 76, 60, and 54% of the respective tested intensities.
3.3.1. Cardiac Dynamics During Global Illumination
The optical mapping analysis of the 10ms as well as 1 s
stimulation experiments combined with the analysis of tlast in
1 s pulse attempts led to identify two preferential mechanisms
for global optical cardioversion. The first mechanism consists
of a cardioversion that happens on the onset of illumination,
mainly annihilating the spiral by the depolarization and following
refractoriness of the cardiac tissue (Figure 5). While in the
second mechanism, an unpinning and disturbance of the
spiral can be observed (Figure 6), with the elimination of the
spiral taking place at the mid and late stimulation period.
Optical mapping data showing the two mechanisms could be
found in the (Supplementary Material Movies 2, 3). As the
dominant mechanism the annihilation was observed for both
pulse duration 10ms and 1 s, and took place in 90% of all
cardioversions using 1 s pulses (N = 120). This mechanism
included a tlast = 58± 19ms. In contrast, the second mechanism
was only observed in the 1 s pulses with an averaged tlast =
296± 122ms. Analyzing the MAP recordings led to a clear
distinction between the two mechanisms, whereby the number
of arrhythmic excitation peaks during tlast was ≤ 2 for 86% of
all the annihilation observations, while all the unpinning cases
presented > 4 arrhythmia cycles during tlast .
4. DISCUSSION
The control of spatiotemporal cardiac regimes and the influence
of the thereto applied electrical pulses have been investigated
extensively in theory and experiment in the last decades
(see e.g., Pumir and Krinsky, 1999; Takagi et al., 2004). In
consequence, especially the diminishment of adverse side effects
of high-energy electrical shocks, like e.g., electroporatic cell
membrane disturbances, while keeping a very high success
rate has been highly prioritized. In this manner, Janardhan
et al. introduced a low-energy defibrillation approach to
successfully terminate ventricular tachycardia (VT) applying
multistage organized shocks (Janardhan et al., 2012). Thereby
they eliminated the phase dependence of shock application,
which is crucial for single shock therapy in VT. Furthermore,
the possibility to control cardiac excitation dynamics by
applying multi-centered new activation origins was proposed
as one auspicious approach (Pumir et al., 2007; Luther
et al., 2011). Luther et al. impressively showed that recruiting
multiple pacing sites has remarkable success in counter-
steering arrhythmic regimes, which in return makes tissue
protective defibrillation feasible. Against this background, non-
electrical approaches would benefit both the development
of tissue protective defibrillation and the investigation of
mechanistic associations without unpredictable worsening side
effects. Cardiac optogenetics with its light initiated depolarization
and accordingly hyperpolarization fulfills this position as a
suitable tool to characterize mechanisms underlying multi-
site pacing. Considering the complex non-linear dynamics of
cardiac arrhythmia, photostimulation convinces with the highly
controllable temporal as well as spatial resolution. Compared
to conventional electrical approaches, the direct interaction of
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FIGURE 2 | Dependency of pulse duration and light intensity as well as pulse
energy in global optogenetic pacing. (A) The three-dimensional plot illustrates
the averaged success rate ± SEM of 1:1 capture in dependency of
investigated combinations of light intensity and pulse duration (as indicated in
Table 1). In this view the variation of measured capture rates is clearly visible,
but still approving the dependency of successful 1:1 capture of light intensity
and pulse duration. In the x-y section are the most efficient combinations
marked, which is visualized in a plain view in the next panel. (B) Shown are the
most efficient combinations of required light intensity and energy for different
pulse duration values (N = 6). The analysis shows a nearly constant energy,
but an increase in intensity when the pulse duration is shortened.
light with optogenetic cardiac tissue can trigger excitation in
single cardiomyocytes or united cell structures without activating
the surrounding tissue structures or inducing critical Faraday
reactions (Ambrosi and Entcheva, 2014). Here, we presented
a setup to investigate arrhythmia termination using global
illumination. The feasibility of photon initiated cardioversion
was shown recently by Bruegmann et al. (2016), Crocini
et al. (2016), and Nyns et al. (2016). Concentrating mainly
FIGURE 3 | Arrhythmia classification on the basis of electrical signal analysis.
Shown are exemplary traces of MAP measurements (in red) for (A) sinus
rhythm, (B) non-sustained and (C) sustained arrhythmia. Green overlay
indicates part of the electrical pacing used to induce arrhythmia.
on low-numbered multi-site pacing Crocini et al. implemented
a mechanistic approach using pulse series of an arrhythmia-
specific light pattern that enabled cardioversion using a total
amount of 1.8mJ. In comparison the required light intensities
up to 40mWmm−2 exceeded the highest intensity implemented
in our experiments by more than the 30-fold. Furthermore,
Bruegmann et al. described an illumination protocol applying 1%
of the light intensity used by Crocini et al., but with a highly
increased pulse duration of four pulses of 1 s with 1–5 s in-
between accounting for a total amount of energy of 228.8mJ.
Having this in mind, in our experiments we concentrated on
the characterization of the separate parameter combinations.
In order to do so, the global stimulation of the whole cardiac
tissue represents the maximum number of pacing sites available
and thus it is comparable to conventional high-energy electrical
defibrillation approaches. We showed the impact of illuminating
the epicardial surface by pacing with the lowest intensities
published so far. An interesting result is that the energy
required to pace both globally and locally remained constant
for each of the methods (98± 5 µJ and 2.8± 0.6 µJ, respectively)
and increased with a growing stimulation area. Certainly, the
excitation origin depends on different factors such as wavelength
or light propagation characteristics. An interesting observation
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FIGURE 4 | Global illumination for cardioversion. (A) Shows the pseudoECG
signal during arrhythmia evocation via electrical pacing and termination using
global illumination (green overlay indicates electrical pacing at 50Hz, 30
(Continued)
FIGURE 4 | pulse). The arrhythmic conditions were terminated with a 1 s
stimulation pulse (indicated in blue), during which the normal sinus rhythm
already returned. (B) Summary of the influence of intensity and pulse duration
on cardioversion attempts. Successful optogenetic defibrillation rates
(percentage of successful attempts reported as mean ± SEM, N = 6).
(C) Visualizes the effect of the termination pulse shown in (A) in more detail.
Two time points were defined in order to characterize the moment of
arrhythmia termination for the 1 s pulses: tlast (green arrow), which denotes the
last peak of the arrhythmia and tsin (brown arrow), which denotes the first peak
of the sinus rhythm during optogenetic stimulation. (D) Charts indicating the
effect of intensity on cardioversion times in percentage of arrhythmia
terminated in those periods of tlast (left) and tsin (right) for 0.56mWmm
−2
(N = 47), 0.25mWmm−2 (N = 40), 0.08mWmm−2 (N = 33).
during global photostimulation is the correlation between
increasing light intensity and rising efficiency of cardioversion.
Lilienkamp et al. introduced in silico results similar to our
experimental findings, which can give hints that the overall size of
an excitable medium has a direct effect on the lifetime of chaotic
spatiotemporal dynamics, like the ones seen during arrhythmia
(Lilienkamp et al., 2017). One possible explanation could be the
change in penetration depth when using higher light intensities
for photostimulation, hence depolarizing a greater number of
cells and creating a thicker reversible conduction pattern. This
was also described by Watanabe et al. in experiments with
ventricular slices, where they showed a temporal decrease on the
effective size available for the arrhythmia to wander (Watanabe
et al., 2017). In their work, Watanabe et al. proved that by
increasing the transmurality of illumination, the chances of
terminating an anatomical re-entry on the slices increased. This
effect could be lead back to the indispensable fact of reaching the
critical cell number for excitation evocation (Zipes et al., 1975). In
contrast, a varied pulse duration at constant light intensity might
prolong the depolarization of the stimulated layers of cardiac
tissue without effectively changing the size of the stimulated
cardiac tissue (Bruegmann et al., 2010).
Optogenetic intensity-dependent effects have been recorded at
the level of single cells, quasi-two dimensional cell cultures and
organs (Bruegmann et al., 2010; Nussinovitch et al., 2014; Burton
et al., 2015; Nussinovitch and Gepstein, 2015; Zaglia et al., 2015).
Accordingly, the effect of light intensity as described by tlast for
the 1 s pulses could be explained by a theoretical combination of
the amount of cells excited, the applied photocurrents and the
conduction velocity of a generated excitation wave (Bruegmann
et al., 2010; Burton et al., 2015; Zaglia et al., 2015). Moreover,
the evidence showing that the majority of defibrillations took
place during the onset of stimulation could be explained by the
Channelrhodopsin-2 kinetics, since its photo-current reaches a
peak during the first milliseconds of activation before dropping
to a smaller current during continuous illumination (Nagel
et al., 2003; Bruegmann et al., 2010). Yet, the difference on
tsin for each intensity is not likewise obvious, since it could
be more related to the intrinsic sinus period of the heart
than to the light induced effect on cardioversion. On the
other hand, the effect of the pulse duration, even when the
difference seems not to be significant might lead to diverse
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FIGURE 5 | Wave dynamics during short global light pulse (10ms, 0.25mWmm−2, highlighted in blue). Shown are the MAP recording (in red) and optical traces of
several local spots on the ventricles (in black, as indicated in panel I). Optical mapping analysis revealed vortex-like electrical activity on the heart surface (image
sequence I), which is disturbed by global illumination (image sequence II) and thus provoking wave collision resulting in annihilation (image sequence III). Sinus activity
follows after a peak corresponding to depolarization of the whole heart (image sequence IV). The corresponding movie is available as
(Supplementary Material Movie 2).
mechanisms of termination. Presumably, spiral disturbance is
unlikely to happen during short pulses of 10 and 25 ms.
Nevertheless, a longer pulse duration such as 500ms or 1 s can
still disrupt the tachycardia even after the onset of the stimulus,
leading to a higher success rate. According to the biophysics of
ChR2, these light-activated channelrhodopsins are un-selective
for different cations like Ca2+ or Na+ (Schneider et al.,
2015). Due to that fact, long photostimulation pulses probably
lead to an accumulation of action potential relevant cations
causing continuous depolarization to less negative membrane
voltages. This assumption is supported by the fact that 10%
of cardioversions for 1 s stimulus occurred during mid-late
stimulation.
However, the results presented here strengthen the application
of cardiac optogenetics, although some underlying mechanisms
still remain to be part of ongoing research. Especially the
investigation of defibrillation protocols consisting of multistage
anti-fibrillation pacing as well as multi-site pacing strategies
have to be addressed, since such experiments would help
to understand the dependencies of phase-specific pacing and
success rate of arrhythmia termination. Therefore, all ex vivo
experiments and the basic classification of photostimulation
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FIGURE 6 | Optical determination of the second identified mechanism, which was only observed in 1 s pulses (0.25mWmm−2, highlighted in blue). Here the locally
stable spiral activity (image sequence I) is disrupted by the illumination resulting in extrusion of the arrhythmic wave pattern to the boundaries (image sequence II).
Already during photostimulation the sinus rhythm resets (image sequence III) and continues after switching off (image sequence IV). The scale-bars indicate 2mm and
are equal for all images in the corresponding panel. Shown are the MAP recording (in red) and optical traces of several local spots on the ventricles (in black, as
indicated in panel I). The corresponding movie is available as (Supplementary Material Movie 3).
parameter function as a trigger for development, optimization
and evaluation of a controllable as well as flexible light induced
cardiac rhythm management. As a positive effect also the design
of new non-electrical multi-site pacing methods with high
potential of translation into clinically relevant approaches comes
within reach.
4.1. Limitations
With the translation into in vivo conditions in mind, one has
to mention that the ex vivo measurements lack the interference
of blood specific absorption of ChR2 exciting wavelengths.
Consequently, any effects during blue-light photostimulation in
vivo would represent only a superficial excitation. Certainly,
the cardiac excitation conduction is not restricted to epicardial
phenomena but also connected to complex transmural wave
propagation (Christoph et al., 2018). Therefore, near infrared
modulated opsins would support the translation of ex vivo
experimental results into clinically relevant in vivo attempts
(Karathanos et al., 2016). Here we successfully achieved
cardioversion using single pulses of divers pulse duration
by tuning light intensities between 0.56 and 1.1 mWmm−2,
delivering total energies 3–153.6 mJ to the epicardium. The
importance of this low-intensity, pulse duration versatility relies
on the fast spatiotemporal dynamics of arrhythmia, where the
optimal duration of the stimulus could be arrhythmia-specific
dependent. That would also result in a smaller amount of light
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being delivered to the cardiomyocytes located transmurally. The
more precise estimation of excited cells within the ventricular
wall and the characterization of light propagation through
cardiac tissue are subject of current research projects. In
the presented study we only examined murine hearts, for
which reason the presented parameter findings can solely be
considered as species specific. For larger species with much
thicker ventricular walls or fatty epicardial regions the light
intensity actually impacting light-sensitive cardiomyocytes will
differ significantly. However, the gotten insights and general
conclusions, like the fact that illuminating the whole epicardial
surface will result in a decrease ofminimum light intensity should
be accountable also for larger species.
Furthermore, induced photochemical reactions during
illumination are possible sources of direct cell response (Lubart
et al., 2007). Lubart et al. showed that especially visible light
(400 nm to 700 nm) could stimulate photobiomodulation and
photosensitization in cardiomyocytes. These processes are
inter alia initiated by generation of reactive oxygen species,
which in return can lead to a change of the redox state of the
cardiac cell and thus have indirect influence on the calcium
induced calcium release (CICR) via redox sensitive L-type
calcium channels. Although, compared to the energy used by
Lubart et al. with 3.6 J cm−2 the total energy applied for global
illumination in this study was 0.01–0.61 Jcm−2, which may have
alleviated photochemical effects. Hence, the measurement and
characterization of potential photobiomodulation with regard
to repeated rapid photostimulation are considered for ongoing
projects.
Experiments including optical mapping were done
with Blebbistatin, which reduces motion artifacts due to
its electromechanical uncoupling function. Since we used
stimulation light of a blue wavelength (470 nm) it is important
to mention, that the uncoupling effects of Blebbistatin could be
reversed by blue light illumination (Fedorov et al., 2012). In our
experiments we did not observe such light induced effects on
the motion inhibition, which could be related to the fact that
Fedorov et al. used much shorter wavelengths for illumination
than we applied. This observation was also published by
Swift et al. (2012). Nevertheless, it should be emphasized that
Blebbistatin does possibly alter the metabolic state of ischemic
cardiomyocytes (Swift et al., 2012).
5. CONCLUSION
According to recent cardiac optogenetic studies the usage of
photodefibrillation seems to be feasible (Bruegmann et al.,
2016, Crocini et al., 2016; Richter et al., 2016). Here we
investigated for the first time the effects of global optogenetic
epicardial illumination which benefits from the larger area
covered to decrease the intensity required to stimulate the
heart. In consequence, we managed to terminate arrhythmic
excitation patterns using pulse lengths spanning three orders of
magnitude, demonstrating an efficient and versatile low-intensity
and low-energy method to investigate arrhythmia dynamics and
manipulation. Besides, we observed two different mechanisms
leading to optogenetic cardioversion, which exhibit not the same
behavior than electrical cardioversion.
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The use of global illumination to terminate arrhythmias did result in a drop in intensity or
pulse duration required compared to previous optogenetic defibrillation approaches [12, 19].
Naturally, the drawback of this method is that illuminating the whole epicardial surface could
lead to technical challenges. However, if global illumination is achievable, we have shown
here that it offers versatility between the duration of the pulse and intensity applied without
the need of high intensities.
We also took an extra step into the mechanistics behind optogenetic cardioversion and
classified termination into either annihilation or perturbation, depending on the time it took
before the arrhythmia signal disappeared. This classification can still have room for improve-
ment, but what was clearly evident is that the majority of terminations take place within the
first 100 ms. Therefore, we dedicated Chapter 9 to analyze a larger number of arrhythmia
termination times, since it could give a hint for optimizing the stimuli and the processes of
optogenetic arrhythmia termination.
Combining optical mapping with optogenetic stimulation allowed us to image the differ-
ences of annihilation and perturbation [63]. However, there are still some difficulties found in
order to obtain a clear signal from the dye while spontaneously optogenetically stimulating the
heart. Therefore, for this work further processing of the optical mapping data was required,
since the voltage dye signal is shifted due to the blue light and in the case of more smooth
analysis or investigation of smaller voltage changes on the epicardium this could become a
greater limitation. In addition, as mentioned in Chapter 6 sections 6.2.1 and 6.2.2, blebbistatin
has an effect on both light attenuation and in the stimulation threshold of ChR2 mice hearts. In
the same line, blebbistatin has been shown to affect conductivity in cell cultures [83], decrease
susceptibility of cardiac arrhythmia in mice hearts [4] and affect induction of fibrillation in
rabbit hearts [10]. Considering all the points mentioned before, it is of high importance that
any optogenetic experiment performed using optical mapping and blebbistatin consider po-
tential effects on the illumination thresholds and other electrophysiological measurements and
results.
Now, that there is a better understanding on how arrhythmias behave under global illu-
mination, I envision two ways of moving forward in cardiac optogenetic research. 1) A step
into structured illumination would provide more insights into the control of arrhythmias using
light. Even though there have been different studies employing specific illumination patterns
and its capabilities [19, 50, 15, 77], the field has still to exploit the spatio-temporal advantages
of optogenetics in order to explore initiation, behavior and termination of cardiac arrhythmia
and cardiac electrophysiology in general [27, 69, 97]. Nevertheless, 2) it is important to also
consider larger animal models. As described during the introduction and also tested in the light
absorption experiments, ventricular thickness and light attenuation blood and other structures
of the heart will play a major role in the efficiency of optogenetic arrhythmia treatment. Test-
ing how larger light-sensitive hearts respond to methods such as global, local and structured
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illumination will have a critical impact on the future of optogenetics as a potential therapy.
In conclusion, we designed an experimental setup capable of panoramic stimulation of
ChR2 transgenic mice heart. With this we showed that global illumination requires shorter
pulses and smaller intensities to efficiently terminate arrhythmias. Furthermore, we inspected
the temporal behavior in which optogenetics leads to cardioversion. Either by annihilation,
taking place early or perturbation, taking longer time.
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8.1. Introduction and Aim
Arrhythmias can be classified based on the morphology of the electrical signal recorded,
with a monomorphic signal showing a repetitive pattern and a polymorphic showing temporal
changes in their morphology or frequency (Figure 8.1). The repetitive pattern in a monomor-
phic signal suggests a stable origin of tachycardia from a focus or structural substrate for
example generated from the re-entrant activity of a stable spiral in one of the ventricles. A
polymorphic signal has a continually changing signal which suggests a varying ventricular
activation sequence for example generated by one or even more drifting spirals [21, 37, 75].
Figure 8.1.: Monomorphic and polymorphic ventricular tachycardia in the mouse heart.
Monophasic action potential signals obtained from contact electrodes of ChR2-
mice Langendorff-perfused mice hearts. On the left an example of a monomorphic
VT and on the right polymorphic VT. Pinacidil was used to induce arrhythmia as
reported in the Materials and Methods section. Bars represent 100 ms.
Different studies using electrical cardioversion have shown that the energy required
to terminate an arrhythmia depends on the morphology, with monomorphic arrhythmias re-
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vealing lower thresholds compared to the more complex polymorphic events [93, 42]. Even
though in optogenetics this effect has not been thoroughly investigated, Nyns and colleagues
revealed that termination of ventricular arrhythmia using single 470 nm light pulses of 1 sec-
ond in rat hearts transduced with the red-activatable channelrhodopsin (ReaChR) terminated
97% of monomorphic arrhythmias compared to 57% of the polymorphic cases [61].
Since different arrhythmia types have also been observed in mice [53, 84], my next
step was to investigate the effect of the arrhythmia morphology on the efficacy of optogenetic
cardioversion. The second part of the results of this chapter is devoted to the investigation of
the arrhythmia morphology on the success of the termination attempt.
The first part of this Chapter focuses on the impact of the illumination time based on
arrhythmia cycle length. In order to investigate this, the concept of tlast which was defined in
Chapter 7 as the time it takes to terminate an arrhythmia from the beginning of stimulation
until the last peak of the arrhythmia. In the same Chapter it was shown that 86% of the
arrhythmias terminated with a single 1 s pulse using the global stimulation setup exhibited ≤
2 arrhythmia cycles before being terminated, a term we called arrhythmia annihilation [67].
Considering this I wanted to explore whether the efficiency of arrhythmia termination could
depend on the number of arrhythmia cycles/periods the heart is illuminated.
8.2. Results
8.2.1. Illumination time based on arrhythmia cycle length
As mentioned before, 86 % of all the successful cardioversions using 1000 ms took place
within 2 arrhythmia cycles from the beginning of stimulation. Therefore, I hypothesized that a
global stimulation lasting 2 arrhythmia periods should be sufficient to return the heart rhythm
into its sinus state. In order to investigate the influence of the illumination duration based on
arrhythmia periods on the cardioversion success rate, I opted to test the efficiency of pulses
lasting 5 ms, 40 ms, 80 ms and 250 ms which corresponds to approximately 0, 1, 2 and 6
arrhythmia periods as the mean arrhythmia frequency is farr = 24 ± 5 Hz (period ∼40 ms). A
representative example of each of the pulses tested is shown in Figure 8.2, where as anticipated
the 5 ms pulse covers less than an arrhythmia period, the 40 ms illuminates for one period,
80 ms around two cycles and 250 ms will be covering more cycles.
Figure 8.3 A plots the results obtained for the analyzed pulses lengths. Interestingly,
both 40 ms and 250 ms showed the highest efficiency at 71 %, while 5 ms pulses showed the
only significant drop in efficiency and terminated only 30 % of the tachycardia induced. Since
our main reference to choose the pulse lengths was based on the chances of an arrhythmia
being terminated within 2.5 arrhythmia cycles or less, we also analyzed this event for each
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Figure 8.2.: Optogenetic cardioversion based on arrhythmia cycles. Examples of pulse
widths of (A) 5 ms, (B) 40 ms, (C) 80 ms and (D) 250 ms. Black represents ECG
signal and blue pulse stimulation, black line marks 100 ms.
case. All the pulses tested, independent of the width, terminated at least half of the arrhythmia
in this manner, while more than 70 % of the cases of the 40 ms and 80 ms took place in this
range (Figure 8.3 B).
Figure 8.3.: Arrhythmia cycles termination rate. (A) The efficiency for 5, 40, 80 and
250 ms pulses. Reported as mean ± s.e.m., N = 6 mice, each data point repre-
sents one heart with n = 10 attempts. Performed Dunn’s multiple comparisons
test (*p<0.05). (B) Percentage (%) of terminated arrhythmias within 2.5 arrhyth-
mia cycles from the beginning of stimulation. (C) Cardioversion success rate
grouped by morphology. Monomorphic ventricular tachycardia (MVT) in blue,
polymorphic ventricular tachycardia (PVT) in red. Fisher’s exact test performed
for comparison (*p<0.05, **p<0.01, ****p<0.0001).
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8.2.2. Optogenetic Cardioversion of Monomorphic and Polymorphic
Ventricular Tachycardia
Termination based on cycle length with constant intensity
As a next step to our inspection on the effect of the arrhythmia cycles used as pulse
length on Global Optogenetic Cardioversion (G.O.C.), we analyzed the efficiency of this tech-
nique to terminate arrhythmia based on morphology. Accordingly, all the arrhythmia from the
four explored pulse lengths (n = 240) were classified into either monomorphic (Figure 8.1 A)
or polymorphic (Figure 8.1 B) tachycardia, revealing that 61 % of the arrhythmia belonged to
the first group. Also, G.O.C. at this light intensity was evidently more efficient terminating
monomorphic than polymorphic arrhythmia (76 % vs 32 % success rates).
Furthermore, by evaluating morphology dependence for each pulse length separately an
significant increased capability to terminate monomorphic arrhythmias was observed in all the
cases Figure 8.2 C, with observed similar rates when illuminating for 40 ms, 80 ms and 250 ms.
This again demonstrated that efficiency for the three pulses greater than the arrhythmia period
was alike.
Effect of intensity on mono- and polymorphic VT termination
Since there was no difference found in the termination of mono- and poly- morphic
arrhythmias with the pulse lengths tested, I opted to investigate using greater differences, such
as 10 ms, 100 ms and 1000 ms, and at the same time vary the intensity for each of the pulses.
In a similar manner, arrhythmias from previously performed experiments were classified and
group before determining the termination efficiencies.
The results are illustrated in Figure 8.4, which is composed of two rows. The top
row displays the termination success rates of ventricular tachycardia using three different
light intensities of 1000 ms, 100 ms and 10 ms for illumination intensities of 0.56 mW/mm2,
0.25 mW/mm2 and 0.08 mW/mm2. The bottom row displays the efficiency of termination
divided by morphology of arrhythmia (mono- or polymorphic ventricular tachycardia) of
the same experiments. Classification of the arrhythmias resulted in 60-80% of the cases
as monomorphic arrhythmia, depending on the subgroup of intensity/pulse-width observed.
Also, regardless of the subgroup, polymorphic events were less frequent for all the groups
analyzed.
The longest pulse width analyzed was 1 second. For this case the termination efficiency
of the tested intensities was higher for monomorphic arrhythmia, with a decrease in the differ-
ence for higher intensities (Figure 8.4 A, bottom). Moreover, none of the intensities terminated
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Figure 8.4.: Optogenetic termination rate of monomorphic and polymorphic arrhythmia.
The top row consists of bar plots displaying the general arrhythmia termination
efficiency during global stimulation for single pulses of (A)1000 ms, (B)100 ms
and (C)10 ms shown as mean ± s.e.m. with each dot representing a single heart
with n = 10 termination attempts per intensity (total n = 50). The bottom row
displays the results of the same experiments divided for success rate of monomor-
phic (VT) and polymorphic (PVT) ventricular tachycardias of each combination
of pulse width and intensity. The n-number indicates the total number of arrhyth-
mias observed for each group. For arrhythmia termination performed one-way
ANOVA (*p<0.05). For morphology comparison performed Fisher’s exact test
(****p<0.0001)
less than 85% of monomorphic events and for the lowest intensity of 0.08 mW/mm2 the ter-
mination efficiency for monomorphic arrhythmia was 88% compared to 25% in polymorphic.
Decreasing the pulse width to 100 ms resulted in a less evident difference in efficiencies
8.4 B), where again the termination success was higher for the less complex arrhythmias and
the most clear case was in the lowest intensity with 30% of MVT terminated compared with
a drop to 15% of PVT. Lastly, using 10 ms flashes resulted in higher cardioversion efficiency
for polymorphic arrhythmias for the highest intensities but in a similar fashion, for the lowest
intensity it was an evident difference with monomorphic arrhythmia being terminated 16% of
the times compared to 0% success in the case of polymorphic arrhythmias 8.4 C). However,
for both the 100 ms and 10 ms cases is difficult to draw any conclusions since the number of
PVT was lower.
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In summary, using the lowest intensity of 0.08 mW/mm2 for any pulse lengths resulted
in termination rates which are systematically larger for arrhythmias with a monomorphic ECG
pattern compared to arrhythmias with a polymorphic pattern. Moreover, at this intensity only
the pulses with duration of 1 s were able to terminate efficiently at 88% compared to the
shorter pulses which both terminated less than one third of the attempts. For the middle inten-
sity of 0.25 mW/mm2 the efficiency is greater for monomorphic arrhythmia using 1 s pulses,
but decreases for 100 ms long pulses and changing to a higher termination of polymorphic ar-
rhythmia for the shortest 10 ms pulses. For the highest intensity of 0.56 mW/mm2 there was
no clear difference of termination for any morphology in any of the three pulse widths tested. I
conclude that 1) longer pulses facilitate monomorphic arrhythmia termination, 2) when using
low intensities, there is higher chance of monomorphic arrhythmia termination than polymor-
phic arrhythmia termination and 3) for higher intensities there are no significant differences in
termination rates. As previously mentioned, it is difficult to obtain a representative statistical
analysis for some cases since the number of polymorphic VT was considerable lower.
8.3. Discussion & Conclusions
At first, we investigated the role of the pulse lengths based on tachyarrhythmia cycles
in global optogenetic cardioversion. Our experiments revealed that for the intensity tested,
the three pulses that were at least as long as an arrhythmia period showed comparable rates
of cardioversion, independent of the morphology of the arrhythmia. In a similar manner,
our previous experiments [67] (Chapter 7) using 0.79 mW/mm2 showed a drop only from
95% to 85% when decreasing the pulse width from 500 ms to 25 ms. Results from the same
experiments suggest that the differences in success between pulse widths becomes broader for
smaller intensities, explaining the evident contrast between the 5 ms long attempts and the rest
of the widths compared. For the experiments performed under these conditions a pulse of at
least one cycle length increase the success substantially. However, further experiments using
other intensities and pulses are needed in order to strengthen this theory.
Interestingly, for both the shortest pulse of 5 ms and the longest pulse of 250 ms, car-
dioversion took place after 2.5 cycles in more than 50 % of the cases. This offers a first
hint of a possible common mechanism behind global optogenetic cardvioversion. One of the
drawbacks of counting the cycles is that arrhythmias can show different frequencies and poly-
morphic arrhythmias might not have a single frequency, therefore a better way to investigate
termination is by looking into how long does a pulse of light takes to terminate an arrhythmia.
Chapter 9 is focused on analyzing this specific period of time, the role of intensity and pulse
length on this task and the possibility of a common mechanism behind this specific span of
time.
The first grouping of monomorphic and polymorphic arrhythmia for the arrhythmia cy-
cles with an intensity of 0.25 mW/mm2 showed higher success rates for monomorphic tachy-
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cardia, for all the pulse lengths tested. As well, varying the intensity for the 1 s stimuli evi-
denced the same behavior. However, shortening the pulses made this conclusion uncertain. A
theory could be that the termination of monomorphic arrhythmias is both intensity and pulse
width dependent, in a way that a longer pulse can compensate for a low intensity, and that the
termination of polymorphic arrhythmias depends mainly on the intensity of the stimulus.
One of the limitations of the morphology experiments is that the number of polymorphic
events can vary per heart and in most of the cases it is lower than the number of monomorphic
arrhythmia. Therefore, this analysis could benefit from a larger number of experiments, or
larger number of cardioversion attempts per heart. Moreover, morphology classification was
performed visually, which could lead to error in certain cases. Considering there is a wide
spectrum of arrhythmia morphologies, it can be challenging to develop a tool for automatic
classification but consistency in classification would be increased.
Both of the analysis performed in this chapter -arrhythmia cycle and morphology dependency-
can potentially lead to interesting and revealing results. However, they both need further ex-
periments that can help us better understand the roles played by the intensity and the pulse




9.1. Introduction and Aim
In the previous chapters I have mainly analyzed the effects of light intensity and pulse
width on the success rate of global optogenetic cardioversion. And in Chapter 7 the term
tlast was defined as the time it takes from the beginning of optogenetic stimulation until the
last peak of the arrhythmia (Fig. 9.1 A, B), in other words how long it takes an optogenetic
stimulus to terminate the arrhythmia, and naturally it can only be measured for successful
attempts [67].
Due to the nature of electrical shocks, this parameter could not be determined or mea-
sured. However, it can be observed and characterized in the electrophysiological recordings
of hearts submitted to optogenetic arrhythmia termination. In our publication [67] we already
performed the first analysis on it, and we observed that in optogenetic cardioversions using
pulses of 1000 ms, an increase in light intensity leads to decrease in tlast.
A deeper analysis of tlast could lead to a better understanding of optogenetic cardiover-
sion and simultaneously of cardiac arrhythmia dynamics and behavior. Therefore, I dedicated
this chapter to describe tlast from experiments performed previously, as well as to interro-
gate factors affecting the time it takes to optogenetically terminate an arrhythmia using global
illumination.
9.2. Results
As a first step, I decided to perform the analysis of tlast first from a global or common
perspective, where I pooled together all the cardioversions from different intensities and pulse
widths. Later, I investigated the differences in cardioversion times depending on specific
widths and intensities of the stimuli, as well as the morphology of the arrhythmia.
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Figure 9.1.: Examples of tlast. Monophasic action potential (MAP) signals showing examples
of tlast, defined as the time it takes to terminate an arrhythmia from the moment
an optogenetic stimulus starts. In (A) the tachycardia disappears within the first
100 ms, on the onset of stimulation. While in (B) the tachycardia lasts beyond
100 ms and shows activity while the heart is being illuminated. Black lines de-
note 100 ms, MAP signals are shown in red and global illumination in blue. (C)
Histogram showing the percentage of arrhythmias terminated within a range of
tlast in groups of 50 ms, starting from 1 ms to 50 ms. (n = 417) successful arrhyth-
mia terminations.
9.2.1. Arrhythmia termination takes place in a specific range
In order to have an overview of the range of cardioversion times I examined this feature
for different experiments. tlast from all the experiments used in Chapter 8 (n = 417) were
grouped and plotted in a histogram. Since for the optogenetic cardioversion experiments we
considered a termination attempt as successful when it terminated the arrhythmia within 1 s
from the beginning of stimulation, the histogram obtained consists of bins of 50 ms, with the
firs one considering the range of 1 ms to 50 ms, and the last bin the range of 951 ms to 1000 ms
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(Figure 9.1 C ). Ventricular arrhythmias induced in our experiments present frequencies in he
range 15 Hz to 30 Hz, with an average of 24 ± 5 Hz (mean ± S.D.).
88% of all successful cardioversions took place within tlast≤200 ms, and more specifi-
cally half of all terminations took place in the range between 51 ms to 100 ms. Moreover (not
visible in Fig. 9.1 C), only 2 events (0.5%) were shorter than 25 ms. On the other hand, just
2.4% of the events took place on the second half of the spectrum, between 501 ms to 1000 ms.
Figure 9.2.: Cardioversion times (tlast) divided per group. Grouped histograms showing
the percentage of arrhythmias terminated within a range of tlast in groups of
50 ms, starting from 1 ms to 50 ms. From all successful cardioversions (n = 417),
tlast were grouped. Cardioversions experiments using pulses of 1000 ms (blue),
100 ms (orange), 10 ms (green) were applied using intensities of 0.08 mW/mm2,
0.25 mW/mm2 and 0.56 mW/mm2 and the cardioversion experiments performed
with an intensity of 0.25 mW/mm2 were performed using pulse widths of 5 ms,
40 ms, 80 ms and 250 ms (Figs. 8.3 & 8.4).
Since these results obtained come from arrhythmias being terminated in different groups
of experiments, I also divided the data into groups following the original experiments per-
formed for Chapter 8 (Figures 8.3 A and 8.4 A, B and C) in order to check for similar be-
haviors. The groups are: n = 121 from pulses of 1000 ms, n = 84 from pulses of 100 ms,
n = 70 from pulses of 10 ms, with the three groups with varying intensities of 0.08 mW/mm2,
0.25 mW/mm2 and 0.56 mW/mm2. And the last group of n = 142 with pulses of constant in-
tensity of 0.25 mW/mm2 and varying pulse widths of 5 ms, 40 ms, 80 ms and 250 ms. Figure
9.2 provides a histogram with the events for each group, this histogram only shows the range
from 1 ms to 500 ms (97.6% of the data) but the percentages are still based on the range from
1 ms to 1000 ms.
Consistent with the collective behavior, all groups showed the highest amount of ter-
minations taking place between 51 ms to 100 ms and a tlast≤200 ms in at least 80% of the
cases, with zero to one case below 25 ms. Moreover, 84% of the cases were ≤100 ms for
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the 1000 ms, compared to 48% for the 10 ms group. In any case, this group terminated ar-
rhythmias in ≤200 ms for 88% of the cases. After analyzing tlast by groups of experiments an
analysis of the intensities and pulse widths is detailed on the following section.
9.2.2. Influence of illumination intensity and duration on the
cardioversion time
As a next step I also examined the effect of the intensity and pulse width on tlast. In
order to do so, the cardioversions performed using pulses of 10 ms, 100 ms and 1000 ms
were further divided depending on the intensities applied (0.08 mW/mm2, 0.25 mW/mm2
and 0.56 mW/mm2), obtaining a total of 9 different groups. Considering that the distribution
of cardioversion times has a long tail that could lead to problems when applying a statistical
test, I decided to remove the values that corresponded to the largest 10% of each group before
obtaining the mean values of tlast for each group, plotted in Figure 9.3 A.
Figure 9.3.: Effect of light intensity and pulse width on tlast. (A) Mean values of tlast for
pulses of 1000 ms (blue), 100 ms (orange), 10 ms (green) and varying intensities
of 0.08 mW/mm2, 0.25 mW/mm2 and 0.56 mW/mm2 after removing the 10%
largest values. t-test summaries performed for differences between intensities
within the same pulse width. (B) Summaries of performed t-tests to the mean tlast
for constant intensity and varying pulse widths. Unpaired t-tests performed for
comparisons (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
Regardless of the pulse width, an increase in intensity led to a decrease in tlast. Further-
more, keeping the intensity constant and decreasing the pulse width also leads to an increase
in mean tlast. In consequence, stimulations with the longest pulses and greatest intensities
managed to terminate arrhythmias at a faster pace. Combining these results with the results of
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the termination success rates, it can be concluded that optogenetic cardioversion with higher
efficiency also require less time to terminate arrhythmias.
As a last comparison, I aimed at understanding how the morphology of the terminated
arrhythmia could affect the cardiversion time. Figure 9.4 displays the mean values of tlast
for terminated monomorphic and polymorphic arrhythmia (Figure 8.1). Cardioversions in
monomorphic arrhythmia took in average 99.2 ± 5.7 ms (mean ± S.D.) compared to 135.2 ±
14.4 ms when the terminated arrhythmia presented a polymorphic signal.
Figure 9.4.: tlast of Monomorphic (MVT) and Polymorphic Ventricular Tachycardia
(PVT). Mean values of tlast for all the arhythmias grouped by morphology. Blue
for MVT (n = 324), pink for PVT (n = 93). Unpaired t-test performed for com-
parison (**p<0.01).
9.2.3. Arrhythmic wave alteration after stimulation
Using the optical mapping technique, I compared the electrical recording from the sur-
face electrodes with the optical signals obtained during optogenetic arrhythmia termination as
a manner to complement my investigation of the mechanisms behind optogenetic cardiover-
sion and tlast. Blebbistatin was used to halt the mechanical beating of the heart without stop-
ping its electrical activity and track using the voltage membrane dye Di-4-ANBDQPQ as
described in Chapter 5 and in [67]. In general, optogenetic cardioversion experiments were
performed without application of blebbistatin. At the end of an experiment and only if the
heart was still viable I would record optical mapping measurements.
Since the main characteristic of tlast is that the majority (∼90%) of cardioversions take
place within 200 ms from the beginning of stimulation, I aimed to investigate recordings with
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this feature. In total 9 recordings from 5 different hearts were analyzed. Figures 9.5 and 9.6
are representative of the events identified using optical mapping.
Figure 9.5.: Electrical activity before and during tlast. Caption on next page.
In Figure 9.5 A the monomorphic ventricular tachycardia from the pseudo-ECG is observed
before being terminated using a single pulse of 2 ms that leads to the elimination of the ar-
rhythmia after ∼1.5 arrhythmia cycles from the moment of stimulation and the sinus rhythm
is restored after a period of ∼300 ms of quiescence. The termination of the arrhythmia as
well as tlast are corroborated in Figure 9.5 B where the optical signals of two different pixels
are observed. Moreover, these recordings also show that before the stimulation the two sig-
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Figure 9.5.: Electrical activity before and during tlast. (A) displays the signal obtained from
the surface electrode, representing a pseudo-ECG (red). The ventricular tachycar-
dia disappears after 104 ms from the beginning of stimulation ( tlast). The blue bar
represents the light pulse and the diagonal bars indicate a time lapse of 300 ms.
(B) plots the signals of two pixels obtained from the optical mapping recorded,
these pixels are marked on the first image of (C), which shows four sequences of
images (S1, S2, S3, S4) from before and after the stimulation pulse. The timeline
of the sequences is referenced on the plot in (B). S1 and S2 illustrate the arrhyth-
mic wave before stimulation, while S3 the last wave of the arrhythmia before its
termination, and S4 the repolarization of the heart after the cease in the arrhythmic
activity.
nals displayed different phases but after the pulse of light they are synchronized leading to
cardioversion.
Finally, Figure 9.5 C is composed of different sequences of images, which are the source
of the action potentials in Figure 9.5 B. The corresponding pixels of (B) are marked on first
image of the top left, and at the same time the sequences S1, S2, S3 and S4 of (C) are marked
on the timeplot of (B). In S1 a sequence of activation of the tachycardic can be appreciated,
traveling from the apex to the base of the heart. S2 shows part of the next arrhythmia wave
before being illuminated. S3 represents the wave traveling on the surface of the heart after
stimulation. This wave exhibits a different conformation than the waves prior to stimulation
since it is closing in from both the base and the apex of the heart until it covers the whole heart
and potentially collides outside of the field of view leading to the cessation of the arrhythmic
behavior as observed in S4. The change in the wave’s morphology might be caused by the
stimulation of the Channelrhodopsin-2 on the excitable gaps leading to their depolarization
but also by the opening of channels on the traveling wave that can lead to changes on the
membrane potential.
In Figure 9.6 we can see examples from two other hearts. First, in Fig. 9.6 (A & B) tlast
is longer, taking a total of 186 ms. This can be expected as two full arrhythmia cycles con-
tinued after illumination, compared to only one full cycle in the previous example. However,
what they both have in common is the the change in wave morphology, as the sequence S3
(last depolarization before cardioversion) from the figure displays two wave fronts closing in
leading to their collision with each other. This is manifested again as the synchronization in
the last action potential of the two pixels analyzed, as also seen in the previous figure.
This same behavior can be appreciated in Fig. 9.6 (C & D). A change in the traveling
pathway of the arrhythmic wave is evident, as it is affected by the light stimulus. Moreover,
before illumination the electrical signals coming from the pixels appeared erratic and without
a clear period, but they synchronize and exhiit slower dynamics after stimulation. In this case
there is only one depolarization wave after the light pulse taking a total tlast of 126 ms.
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Figure 9.6.: Arrhythmic wave alteration after illumination. Caption on next page.
9.3. Discussion & Conclusions
Due to the hints of a common mechanism behind global optogenetic cardioversion, I
performed a specific analysis of tlast for all the cardioversion cases (Figure 9.2 & 9.3). Even
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Figure 9.6.: Arrhythmic wave alteration after illumination. Two more examples showing
the electrical activity pf the arrhythmic waves before and after optogenetic stim-
ulation. (A) plots the optical action potentials obtained from (B) where three se-
quences of images are displayed (S1, S2, S3) illustrating the traveling at different
time points. In the same manner, (C) plots the optical action potentials obtained
from (D).
though pulse length, intensity and arrhythmia morphology will all play a role in determining
the success as well as the moment of the cardioversion [12, 19, 67, 61, 88, 60], more than 70%
of the cardioversions materialize in the range between 25 ms to 100 ms, and approximately
90% before the 200 ms mark. This suggests a potential specific process related to this time
lapse taking place in order to terminate an arrhythmia. Considering that only 2 out of 417
arrhythmia were terminated at 25 ms or less, could translate into the process of optogenetic
termination needing a minimum amount of time, with these 2 specific cases arising from
arrhythmias about to self-terminate.
The minimum necessary time of tlast could originate from the events needed in order to
terminate an arrhythmia using optogenetics on global epicardial illumination. Events such as
the depolarization of a specific number of cells and the time needed to reach peak ChR-2 cur-
rents, both which are intensity dependent, proven to affect tlast. At organ scale the mechanisms
leading to optogenetic cardioversion are also time-dependent. Creating a conduction block on
the path of the arrhythmic wave or generating a new wave to collide with it [76], something
that could explain why 1000 ms pulses exhibited shorter and more consistent tlast.
As described in all isolated heart ex-vivo optogenetic cardioversion literature [12, 19, 67,
61], increasing the light intensity and pulse width translates into higher termination rates. As
seen in our tlast analysis, the same parameters will lead to a higher consistency in the termina-
tion times and to a general decrease in this times as seen in the box plots. Therefore, I propose
that one of the parameters of reliable (attempts with higher efficiency rates) optogenetic car-
dioversion techniques should aim to “annihilate” arrhythmias, or in the case of my results, aim
at the 25 ms to 100 ms range where more than 70% of the cardioversions took place. Whether
high-success-rate attempts lead to faster terminations, or vice-versa is not completely clear but
indications show that they are related and probably depend on each other.
The optical mapping analysis of traveling waves demonstrates a modification of the
arrhythmic wave as a result of the optogenetic stimulation with a presumable increase in syn-
chronization of the electrical activity in the heart leading to termination. As explained by Sasse
and colleagues [76], global stimulation increases the chances of illuminating the excitable gap
and creating a new wave that would eventually collide with the arrhythmic wave. Yet another
theory that would not exclude a new wave is that stimulation of Channelrhodopsin-2 modifies
electrophysiological properties of the cardiac tissue such as the conduction velocity and ex-
citability [15] contributing to the alteration of the wave’s morphology and pathwave and aiding
91
9. Cardioversion times
with its termination. Therefore, taking generally one to two arrhythmia periods after stimu-
lation [67] before the new or modified wave collides, conceivably explaining the typical tlast
times manifested. And once again, longer pulses and higher intensities have a greater effect
on the cardiac tissue and therefore on the arrhythmic wave leading to faster terminations.
To conclude, the time it takes for an arrhythmia to be terminated using global optoge-
netic cardioversion has a specific range and it takes place within the first hundreds of millisec-
onds potentially due to an alteration of the electrophysiological properties of both the excitable
and unexcitable tissue. Higher intensities and longer pulses shorten this time, with a higher
effect seen by the intensity. Lastly, and as a consequence, the most successful parameters in
optogenetic cardioversions displayed shorter termination times.
9.4. Contributions
Part of the experiments were performed by the master students Tsima Abou Kors and
Vishalini Vinkatesan during their master thesis projects. I completely designed and supervised








Cardiac optogenetics is a blooming field, with the first demonstrations of control of
cardiac electrophysiology just ten years ago [3, 11] and utility to terminate arrhythmia in iso-
lated heart models showed six years later [12, 61, 19]. However, there is still much to be
learned and understood in the cardiac field using photo-sensitive ion channels. This doctoral
work focused on the termination of arrhythmia using global illumination on isolated ChR-2
transgenic mice hearts. So far mice hearts have been the most common organ-level model
in cardiac optogenetics and channelrhodopsin-2 the main optogenetic tool implemented. Pre-
vious work done from Bruegmann and Crocini [12, 19] set the foundations of this research
project. Almost simultaneously Bruegmann tested different stimulation areas, intensities and
pulse lengths showing the feasibility of optogenetic cardioversion, while Crocini implemented
a mechanisitic design of illumination patterns to stop arrhymthic activity making use of the
spatiotemporal advantages of optogenetics. Therefore, testing a different method to stimulate
the heart in an attempt to terminate arrhythmias would offer new insights and allow compar-
isons with the already obtained knowledge and provide perspectives that can help improve the
general understanding of optogenetic arrhythmia termination. This discussion section gives a
general perspective and potential future experiments, since discussions specific to the results
obtained have been included in each section.
There are some clear advantages and disadvantages of applying global epicardial il-
lumination to terminate arrhythmias. As demonstrated by various groups, irradiation of a
larger area will require lower intensities and shorter pulses to produce an optogenetic response
[96, 19, 67, 11]. The closer optogenetic cardioversion gets to the clinics, the greater the impor-
tance of terminating arrhythmias with lower intensity. As seen in our light attenuation results,
the blood and other heart structures greatly decrease the amount of light penetrating the deep-
est layers of the cardiac walls. Therefore, achieving optogenetic cardioversion in larger animal
models and in humans will be a matter of light delivery as already shown in different in-silico
models [41, 12, 9]. On the other hand, global illumination comes with the technical challenge
of designing a light delivery method in-vivo.
Up to date, optogenetic control has been shown in zebrafish [3], mouse [11, 12, 19, 96,
67, 17, 29, 98, 13, 85] and rat hearts [61, 60, 62], all of them representing small animal models.
Therefore it is safe to assume that optogenetics in larger hearts will come with new physical
and physiological challenges. However, studies like the one made during this doctoral project
give a head start to future investigations. As shown here and in other results, pacing and
cardioversion depend on the area illuminated, the intensity applied and the length of the pulse.
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This can be translated as the volume of cardiac tissue/cardiomyocytes excited over a period
of time. The volume excited will also depend on the sensitivity of the opsin used [55], the
excitation wavelength and on the attenuation properties of the areas of the heart excited.
The analysis of tlast shows a potential common mechanism behind optogenetic car-
dioversion using global illumination. This mechanism might be specific to the combination
of ChR-2 in a mouse heart stimulated with global illumination but at the same time a similar
behavior can be expected from other species. A retrospective analysis of tlast from different
illumination methods tested by other groups would not require extensive work nor further ex-
periments and might complement this study and provide data that could strengthen this theory.
Since tlast is affected by the pulse width and intensity, we can assume that the area illuminated
will also play a role and that smaller areas will take longer to terminate an arrhythmia but we
will still find a constant or common termination time like the one identified in this project.
While no clear effect of the morphology on the efficiency of optogenetic arrhythmia
termination was identified, further experiments could bring deeper understanding to the dif-
ferences. Additionally, mice hearts are less suitable to host arrhythmia [25, 38] and larger
animal studies might be better in clarifying this theory. In a translation to clinics scenario,
patients with identified arrhythmia would benefit from the characterization of optogenetic en-
ergy requirements of different kinds of arrhythmia since patient specific treatments could be
designed.
Last but not least, while other groups have already explored patterned [77, 19] and intra-
mural [98] illumination on isolated hearts, this project aimed to investigate the general and so
far unexplored scenario of global epicardial illumination. Answers obtained from this method
aid prospective research take full advantage of the high spatial resolution offered by optoge-
netics.
The results presented in this doctoral research project have firstly provided new insights
into cardiac optogenetic stimulation, and secondly brought new ideas to explore in the appli-
cation of optogenetics to investigate, control and terminate cardiac arrhythmia.
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In this thesis work I have focused my research on understanding global optogenetic
stimulation as a means to terminate arrhythmia on isolated mice hearts expressing ChR-2. I
hypothesized that compared to local illumination, global illumination would reduce the in-
tensity and the pulse widths necessary to terminate an arrhythmia and would also improve
our knowledge of the mechanisms involved. This research project has covered four different
aspects: first understanding optogenetic stimulation in this mouse model under various condi-
tions, followed by optogenetic arrhythmia termination using global stimulation, to move into
specifics of global optogenetic cardioversion such as the efficiency of monomorphic and poly-
morphic termination attempts and lastly analyzing the time it takes to terminate an arrhythmia
and the factors behind it.
From the first task we can conclude that laboratory chemicals such as dyes and electro-
mechanical uncouplers increase the attenuation of light and will have an effect on optogenetic
stimulation thresholds. Similarly, a heart filled with blood will present higher attenuation
compared to a heart perfused with tyrode, the perfusion solution used in most ex-vivo exper-
iments. Moreover, stimulating the heart requires a minimum energy that will depend on the
pulse length, the intensity of the delivered light and the surface area illuminated. Therefore,
by increasing one of these parameters the others can be decreased and the other way around.
The pacing threshold will also depend on the specific area of the heart stimulated, with the left
ventricle showing a higher threshold than the right ventricle.
Similar to pacing, the success of optogenetic termination using global stimulation will
depend on intensity, area and pulse width. However, the energy required to terminate an
arrhythmia will be larger by at least one order of magnitude. Illuminating the whole epicardial
surface provided us the advantage of decreasing both intensity and total stimulation time,
reaching high success rates with single pulses of 10 ms to 1000 ms using intensities lower
than the intensities needed to pace using optical fibers. Combined with these experiments
we also analyzed for the first occasion the time needed to terminate an arrhythmia (tlast).
Our observations showed that optogenetic cardioversions performed with higher intensities
eliminated arrhythmias sooner, and that the majority of cardioversions took place on the onset
of stimulation with a small percentage happening later. Both events were visible on the surface
of the heart using the optical mapping technique, confirming that stimulation of the excitable




The ratio of arrhythmia termination based on morphology did not give a clear answer on
the differences in termination success between monomorphic and polymorphic arrhythmia.
While long pulses of 1000 ms were able to terminate monomorphic ventricular tachycardia
even with low intensities, for 100 ms and 10 ms no significant differences were found. Since
the number of polymorphic VT measured was lower, a better comparison can be made by
increasing the number of samples. Both morphology analysis and arrhythmia cycle length
analysis offer interesting points for deeper future investigations.
I introduced the term cardioversion time (tlast), and its analysis led to a clear time lapse
for optogenetic arrhythmia termination using global stimulation. 87% materialize ≤ 200 ms
revealing the possibility of a common mechanism behind optogenetic cardioversion. Optical
recordings of the traveling waves on the surface of the heart suggest an alteration of the ar-
rhythmic wave leading to its collision. Moreover, tlast decreased and became more consistent
for higher stimulation intensities and to a lower degree for longer pulse widths.
The research done on different aspects of global illumination as method of optogenetic
cardioversion broadens the understanding, advantages and limitations of optogenetics as a tool
to control and investigate arrhythmias. It answers physical and physiological questions and
opens new research questions, both of clinical relevance setting the ground for investigation
in large animal models.
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[77] M. Scardigli, C. Müllenbroich, E. Margoni, S. Cannazzaro, C. Crocini, C. Ferrantini,
R. Coppini, P. Yan, L. M. Loew, M. Campione, L. Bocchi, D. Giulietti, E. Cerbai,
C. Poggesi, G. Bub, F. S. Pavone, and L. Sacconi. Real-time optical manipulation of
cardiac conduction in intact hearts. The Journal of Physiology, 17:3841–3858, 2018.
ISSN 00223751. doi: 10.1113/JP276283. URL http://doi.wiley.com/10.1113/
JP276283. 22, 73, 96
[78] Franziska Schneider, Christiane Grimm, and Peter Hegemann. Biophysics of Channel-
rhodopsin. Annual Review of Biophysics, 44(1):167–186, 2015. ISSN 1936-122X. doi:
10.1146/annurev-biophys-060414-034014. URL http://www.annualreviews.org/
doi/10.1146/annurev-biophys-060414-034014. 23
[79] Eleanor B Schron, Derek V Exner, Qing Yao, Louise S Jenkins, Jonathan S Steinberg,
James R Cook, Steven P Kutalek, Peter L Friedman, Rosemary S Bubien, Richard L
107
Bibliography
Page, and Judy Powell. Quality of Life in the Antiarrhythmics Versus Implantable De-
fibrillators Trial. Circulation, 105(5):589–594, feb 2002. doi: 10.1161/hc0502.103330.
URL https://www.ahajournals.org/doi/10.1161/hc0502.103330. 27
[80] David Shier, Jackie Butler, and Ricki Lewis. Hole’s human anatomy & physiology.
McGraw-Hill, 1999. ISBN 0-697-34193-3. 7
[81] Daniel C. Sigg, Paul A. Iaizzo, Yong-Fu Xiao, and Bin He. Cardiac Electrophysiology
Methods and Models. Springer US, Boston, MA, 2010. ISBN 978-1-4419-6657-5. doi:
10.1007/978-1-4419-6658-2. 7, 8, 9, 13, 17, 18
[82] Warren Smith and Margaret Hood. Arrhythmias, pages 316–341. Butterworth-
Heinemann, 2007. ISBN 0-7506-7572-1. doi: 10.1016/B978-075067572-7.50024-2.
13, 15
[83] Susan A. Thompson, Craig R. Copeland, Daniel H. Reich, and Leslie Tung. Mechan-
ical coupling between myofibroblasts and cardiomyocytes slows electric conduction in
fibrotic cell monolayers. Circulation, 123(19):2083–2093, 2011. ISSN 00097322. doi:
10.1161/CIRCULATIONAHA.110.015057. 54, 73
[84] Dhananjay Vaidya, Gregory E. Morley, Faramarz H. Samie, and José Jalife. Reentry
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